

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2015301782 B2**

(54) Title
Method for the treatment of depression

(51) International Patent Classification(s)
A61K 31/135 (2006.01) **A61K 31/35** (2006.01)
A61K 31/137 (2006.01) **A61M 11/00** (2006.01)

(21) Application No: **2015301782** (22) Date of Filing: **2015.08.12**

(87) WIPO No: **WO16/025581**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	62/036,896		2014.08.13		US

(43) Publication Date: **2016.02.18**

(44) Accepted Journal Date: **2020.09.03**

(71) Applicant(s)
Janssen Pharmaceutica NV

(72) Inventor(s)
Li, Qingqin S.;Drevets, Wayne C.

(74) Agent / Attorney
Shelston IP Pty Ltd., L 9 60 Margaret St, Sydney, NSW, 2000, AU

(56) Related Art
US 20140093592 A1
DE 102007009888 A1
KYLE A.B. LAPIDUS ET AL, "A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder", BIOLOGICAL PSYCHIATRY, (2014-04-03), vol. 76, no. 12, doi:10.1016/j.biopsych.2014.03.026, ISSN 0006-3223, pages 970 - 976
US 20070287753 A1
Tansey et al; Biol Psychiatry, vol. 73, 2013, pp. 679-682.



(51) International Patent Classification:

A61K 31/135 (2006.01) A61M 11/00 (2006.01)
A61K 31/137 (2006.01) A61K 31/35 (2006.01)

(21) International Application Number:

PCT/US2015/044830

(22) International Filing Date:

12 August 2015 (12.08.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/036,896 13 August 2014 (13.08.2014) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors: LI, Qingqin, S.; 1125 Trenton-Harbourton
Road, Titusville, New Jersey 08560 (US). DREVETS,
Wayne, C.; 1125 Trenton-Harbourton Road, Titusville,
New Jersey 08560 (US).

(74) Agents: PLANTZ, Bernard, F. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHOD FOR THE TREATMENT OF DEPRESSION

(57) Abstract: The present invention is directed to a method for the treatment of depression, for example, treatment of resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at single nucleotide polymorphism (SNP) rs4306882. Specifically, the method comprising determining the presence of a G or T allele at rs4306882, and administering a dosing regimen of ketamine or esketamine, wherein the dosing regimen is adjusted to provide a higher dose and/or greater frequency of the ketamine or esketamine to those patients with the G allele (rather than T allele) at the polymorphic site of rs4306882. Further disclosed is a method for predicting whether a patient suffering from depression is genetically predisposed to poorly respond to antidepressants which block the reuptake of monoamine neurotransmitters, comprising genotyping said patient to determine the patient's genotype at SNP rs4306882.



METHOD FOR THE TREATMENT OF DEPRESSION

Cross Reference to Related Applications

This application claims the benefit of priority under 35 U.S.C. §119(e) to
5 U.S. Provisional Application 62/036,896, filed August 13, 2014, the disclosure
of which is herein incorporated by reference in its entirety.

Sequence Listing

The instant application contains a Sequence Listing which has been
submitted electronically in ASCII format and is hereby incorporated by
10 reference in its entirety. Said ASCII copy, created on August 11, 2015, is
named "PRD3345WOPCT_SeqListing.txt" and is 56 kilobytes in size.

Field of the Invention

The present invention is directed to method for the treatment of
depression, for example, treatment resistant depression; wherein the treatment
15 regimen is adjusted depending on the patient's genotype at SNP rs4306882.

Background of the Invention

Major Depressive Disorder is defined as the presence of one of more
major depressive episodes that are not better accounted for psychotic disorder
or bipolar disorder. A major depressive episode is characterized by meeting
20 five or more of the following criteria during the same 2 week period which
represent a change in functioning and include at least depressed/ sad mood or
loss of interest and pleasure, indifference or apathy, or irritability and is usually
associated with a change in a number of neurovegetative functions, including
sleep patterns, appetite and body weight, motor agitation or retardation, fatigue,
25 impairment in concentration and decision making, feelings of shame or guilt,
and thoughts of death or dying (Harrison's Principles of Internal Medicine,
2000). Symptoms of a depressive episode include depressed mood; markedly
diminished interest or pleasure in all, or almost all, activities most of the day;
weight loss when not dieting or weight gain, or decrease or increase in appetite
30 nearly every day; insomnia or hypersomnia nearly every day; psychomotor
agitation or retardation nearly every day; fatigue or loss of energy nearly every
day; feelings of worthlessness or excessive or inappropriate guilt nearly every
day; diminished ability to think or concentrate, or indecisiveness, nearly every

day; recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide. Further, the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. (*Diagnostic and Statistical*
5 *Manual of Mental Disorders*, 4th Edition, American Psychiatric Association, 1994)

Current treatment options for unipolar depression include monotherapy or combination therapy with various classes of drugs including mono-amine oxidase inhibitors (MAOI), tricyclic antidepressants (TCA), serotonin specific
10 reuptake inhibitors (SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), , noradrenaline reuptake inhibitor (NRI), "natural products" (such as Kava-Kava, St. John's Wort), dietary supplement (such as s-adenosylmethionine) and others. More specifically, drugs used in the treatment of depression include, but are not limited to imipramine, amitriptyline, desipramine, nortriptyline,
15 doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, chlomipramine, fluoxetine, citalopram, sertraline, paroxetine, tianeptine, nefazadone, venlafaxine, desvenlafaxine, duloxetine, reboxetine, mirtazapine, phenelzine, tranylcypromine, and / or moclobemide. Several of these agents including, but not limited to, serotonin reuptake inhibitors are also
20 used when depression and anxiety co-exist, such as in anxious depression.

In the clinic, 40-50% of depressed patients who are initially prescribed antidepressant therapy do not experience a timely remission of depression symptoms. This group typifies level 1 treatment-resistant depression, that is, a failure to demonstrate an "adequate" response to an "adequate" treatment trial
25 (that is, sufficient intensity of treatment for sufficient duration). Moreover, about approximately 30% of depressed patients remain partially or totally treatment-resistant to at least two antidepressant treatments including combination treatments. Increasingly, treatment of treatment-resistant depression includes augmentation strategies including treatment with pharmacological agents such
30 as, antipsychotics (such as quetiapine, aripiprazole, olanzapine, risperidone, and the like), lithium, carbamazepine, and triiodothyronine, and the like; adjunctive electroconvulsive therapy; adjunctive transcranial magnetic stimulation; etc.

Suicide, also known as completed suicide, is the "act of taking one's own life". Attempted suicide or non-fatal suicidal behavior is self-injury with the desire to end one's life that does not result in death. Suicidal ideations are thoughts of ending one's life but not taking any active efforts to do so.

5 Suicidal ideation is the medical term for thoughts about or an unusual preoccupation with suicide. The range of suicidal ideation varies greatly from fleeting to detailed planning, role playing, and unsuccessful attempts, which may be deliberately constructed to fail or be discovered, or may be fully intended to result in death. Although most people who undergo suicidal
10 ideation do not go on to make suicide attempts, a significant proportion do. Suicidal ideation is generally associated with depression; however, it seems to have associations with many other psychiatric disorders, life events, and family events, all of which may increase the risk of suicidal ideation.

Suicidal ideation —may include, for example, suicidal thoughts — but
15 may also include other related signs and symptoms. Some symptoms or co-morbid conditions may include unintentional weight loss, feeling helpless, feeling alone, excessive fatigue, low self-esteem, presence of consistent mania, excessively talkative, intent on previously dormant goals, feel like one's mind is racing. The onset of symptoms like these with an inability to get rid of
20 or cope with their effects, a possible form of psychological inflexibility, is one possible trait associated with suicidal ideation. They may also cause psychological distress, which is another symptom associated with suicidal ideation. Symptoms like these related with psychological inflexibility, recurring patterns, or psychological distress may in some cases lead to the onset of
25 suicidal ideation. Other possible symptoms and warning signs include: hopelessness, anhedonia, insomnia, depression, severe anxiety, angst, impaired concentration, psychomotor agitation, panic attack and severe remorse.

Scales used in the evaluation of suicidal ideation include Beck Scale for
Suicide Ideation (BSS), Columbia Suicide Severity Rating Scale and The
30 Kessler Psychological Distress Scale (K10, which test does not measure suicidal ideation directly, but there may be value in its administration as an early identifier of suicidal ideation. High scores of psychological distress are also, in some cases associated with suicidal ideation.

There are also several psychiatric disorders that appear to be comorbid with suicidal ideation or considerably increase the risk of suicidal ideation. The following disorders have been shown to be the strongest predictors of suicidal ideation /disorders in which risk is increased to the greatest extent: major
5 depressive disorder (MDD), dysthymia, bipolar disorder, post traumatic stress disorder (PTSD), personality disorders, psychosis (anxiety or detachment from reality), paranoia, schizophrenia and drug abuse.

The main treatments for suicidality and / or suicidal ideation include: hospitalization, outpatient treatment, and medication. Hospitalization allows the
10 patient to be in a secure, supervised environment to prevent their suicidal ideation from turning into suicide attempts. In most cases, individuals have the freedom to choose which treatment they see fit for themselves. However, there are several circumstances in which individuals can be hospitalized involuntarily, including circumstances where an individual poses danger to self or others and
15 where an individual is unable to care for one's self.

Outpatient treatment allows individuals to remain at their place of residence and receive treatment when needed or on a scheduled basis. Before allowing patients the freedom that comes with outpatient treatment, physicians evaluate several factors of the patient. These factors include the patient's level
20 of social support, impulse control and quality of judgment. After the patient passes the evaluation, they are often asked to consent to a "no-harm contract". This is a contract formulated by the physician and the family of the patient. Within the contract, the patient agrees not to harm themselves, to continue their visits with the physician, and to contact the physician in times of need. These
25 patients are then checked on routinely to assure they are maintaining their contract and staying out of troublesome activities.

There are also a number of different pharmacological treatment options for those experiencing suicidal ideation. However, prescribing medication to treat suicidal ideation can be difficult. One reason for this is because many
30 medications lift patients' energy levels before lifting their mood. This puts them at greater risk of following through with attempting suicide. Additionally, if a patient has a co-morbid psychiatric disorder, it may be difficult to find a medication that addresses both the psychiatric disorder and suicidal ideation.

Therefore, the medication prescribed to one suicidal ideation patient may be completely different than the medication prescribed to another patient. However, there are several medications that seem to work fairly well for treating suicidal ideation, more particularly antidepressants, including fluoxetine (PROZAC), sertraline (ZOLOFT), paroxetine (PAXIL), fluvoxamine (LUVOX), venlafaxine (EFFEXOR) and nefazodone (SERZONE).

Although research is largely in favor of the use of antidepressants for the treatment of suicidal ideation, in some cases antidepressants are claimed to be associated with increased suicidal ideation. Upon the start of using antidepressants, many clinicians will note that sometimes the sudden onset of suicidal ideation may accompany treatment. This has caused the Food and Drug Administration (FDA) to issue a warning stating that sometimes the use of antidepressants may actually increase the thoughts of suicidal ideation.

Ketamine (a racemic mixture of the corresponding S- and R- enantiomers) is an NMDA receptor antagonist, with a wide range of effects in humans, including analgesia, anesthesia, hallucinations, dissociative effects, elevated blood pressure and bronchodilation. Ketamine is primarily used for the induction and maintenance of general anesthesia. Other uses include sedation in intensive care, analgesia (particularly in emergency medicine and treatment of bronchospasms. Ketamine has also been shown to be efficacious in the treatment of depression (particularly in those who have not responded to other anti-depressant treatment). In patients with major depressive disorders, ketamine has additionally been shown to produce a rapid antidepressant effect, acting within two hours.

The S-ketamine enantiomer (or S-(+)-ketamine or esketamine) has higher potency or affinity for the NMDA reception and thus potentially allowing for lower dosages; and is available for medical use under the brand name KETANEST S.

There remains a need to provide an effective treatment for depression, more particularly treatment resistant depression and / or for the treatment of suicidality, suicidal ideations, and for the prevention of suicide, particularly in the first hours and days after the onset of a major depressive episode.

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

Summary of the Invention

According to a first aspect, the invention relates to a method for the treatment of depression comprising:

- Step A: genetically testing (or genotyping) a patient suffering from depression to determine the patient's genotype at rs4306882;
- Step B: (i) wherein if the patient carries the G allele at SNP rs4306882, esketamine is administered intranasally to said patient at a dosage of about 28 mg to about 32 mg, one to three times per week for up to eight weeks, or
(ii) wherein if the patient carries the T allele at SNP rs4306882, esketamine is administered intranasally to said patient at a dosage of about 28 mg to about 32 mg, two to five times per week for up to eight weeks.

According to a second aspect, the invention relates to a method for predicting whether a patient suffering from depression is genetically predisposed to poorly respond to antidepressants which block the reuptake of monoamine neurotransmitters, comprising genotyping said patient to determine whether the patient has a G allele or a T allele at SNP rs4306882.

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

The present invention is directed to a method for predicting whether a patient suffering from depression, preferably treatment resistant depression, is genetically predisposed to poorly respond to antidepressants, for example antidepressants which block the reuptake of monoamine neurotransmitters
5 such as serotonin, norepinephrine, dopamine, and the like, comprising genotyping of said patient to determine the patient's genotype at SNP rs4306882 (on chromosome 3).

The present invention is further directed to a method for genotyping a patient to determine the patient's polymorphism at SNP rs4306882, comprising
10 the steps of:

Step A: obtaining a biological sample comprising genetic material of the subject, wherein the subject is undergoing or is to undergo antidepressant pharmacotherapy;

Step B: determining the presence of a G or T allele at rs4306882.

15 In an embodiment, the present invention is directed to a method for genotyping further comprising extracting DNA from the biological sample. In an embodiment, the present invention is directed to a method for genotyping wherein the biological sample is a blood sample. In an embodiment, the present invention is directed to a method for genotyping further comprising
20 reporting the determination to the subject, a health care provider, a physician, a pharmacist, a pharmacy benefits manager or an electronic system.

The present invention is directed to a method for the treatment of depression, preferably treatment resistant depression (TRD), comprising:

25 Step A: genetically testing (or genotyping) a patient suffering from depression (preferably treatment resistant depression) to determine the patient's genotype at SNP rs4306882;

Step B: administering a dosing regimen of ketamine or esketamine, wherein the dosing regimen is adjusted to provide a higher
30 dose and / or greater frequency of the ketamine or esketamine to those patients with a G allele (rather than a T allele) at the polymorphic site of SNP rs4306882.

In an embodiment of the present invention, the methods further comprise genetically testing (or genotyping) the patient suffering from depression, preferably treatment resistant depression, to determine the patient's genotype at one or more of the SNPs as listed in Table 3 which follows herein.

In an embodiment of the present invention, the patient suffering from depression, or in need of treatment for depression, is suffering from treatment resistant depression (TRD).

In an embodiment of the present invention, the dosing regimen comprises administration of esketamine, preferably intranasal esketamine. In an embodiment of the present invention, the esketamine is administered at a therapeutically effective amount. In another embodiment, the esketamine is administered as co-therapy in combination with one or more anti-depressants. In another embodiment of the present invention, the co-therapy is administered in a therapeutically effective amount.

In an embodiment of the present invention, wherein the patient in need of treatment is a patient carrying the G allele at SNP rs4306882, the dosing regimen comprises administration of intranasal esketamine at a dose of between about 28 mg and about 32 mg (preferably 28 mg), at an interval of one to four (preferably one to three, more preferably one to two, more preferably one) times per week, for a period of up to about eight weeks.

In another embodiment of the present invention, wherein the patient in need of treatment is a patient carrying the T allele at SNP rs4306882, the dosing regimen comprises administration of intranasal esketamine at a dose of between about 28 mg and about 32 mg (preferably 32 mg), at an interval of two to five (preferably three to five, more preferably four to five) times per week, for a period of up to about eight weeks.


In an embodiment of the present invention, the dosing regimen is administered for one to eight weeks, preferably for one to six weeks. In another embodiment of the present invention, the dosing regimen is administered for two to eight weeks, preferably for two to six weeks, preferably two to four weeks. In additional embodiments of the present invention, the

dosing regimen is administered for one, two, three, four, five, six, seven or eight weeks.

Detailed Description of the Invention

The present invention is directed to methods for the treatment of
 5 depression, more particularly treatment resistant depression, and / or for the treatment and / or prevention of suicidality (e.g. suicidal ideations) comprising genotyping a patient in need thereof (e.g. suffering from depression, preferably treatment resistant depression) and administering ketamine, preferably esketamine, preferably intranasally, according to a dosing regimen which is
 10 selected (preferably optimized) for said patient, based on the patient's genotype at SNP rs4306882, alone or in combination with one or more SNPs, as described in more detail herein.

As used herein, unless otherwise noted, the term "**esketamine**" shall mean the (S)-enantiomer of ketamine, as its corresponding hydrochloride salt,
 15 a compound of formula (I)



also known as (S)-2-(2-chlorophenyl)-2-(methanimino)cyclohexanone hydrochloride.

As used herein, unless otherwise noted, the term "**antidepressant**" shall
 20 mean any pharmaceutical agent which can be used to treat depression. Suitable examples include, but are not limited to mono-amine oxidase inhibitors such as phenelzine, tranylcypromine, moclobemide, and the like; tricyclics such as imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, and the like; tetracyclics such as
 25 maprotiline, and the like; non-cyclics such as nomifensine, and the like; triazolopyridines such as trazodone, and the like; serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, citalopram, citolapram, escitalopram, fluvoxamine, and the like; serotonin receptor antagonists such as nefazadone, and the like; serotonin noradrenergic reuptake inhibitors such as venlafaxine,
 30 milnacipran, desvenlafaxine, duloxetine and the like; noradrenergic and specific

serotonergic agents such as mirtazapine, and the like; noradrenaline reuptake inhibitors such as reboxetine, edivoxetine and the like; atypical antidepressants such as bupropion, and the like; natural products such as Kava-Kava, St. John's Wort, and the like; dietary supplements such as s-adenosylmethionine.,
5 and the like; and neuropeptides such as thyrotropin-releasing hormone and the like; compounds targeting neuropeptide receptors such as neurokinin receptor antagonists and the like; and hormones such as triiodothyronine, and the like. Preferably, the antidepressant is selected from the group consisting of fluoxetine, imipramine, bupropion, venlafaxine and sertraline.

10 Therapeutically effective dosage levels and dosage regimens for antidepressants (for example, mono-amine oxidase inhibitors, tricyclics, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors, noradrenergic and specific serotonergic agents, noradrenaline reuptake inhibitor, natural products, dietary supplements, neuropeptides, compounds
15 targeting neuropeptide receptors, hormones and other pharmaceutical agents disclosed herein), may be readily determined by one of ordinary skill in the art. For example, therapeutic dosage amounts and regimens for pharmaceutical agents approved for sale are publicly available, for example as listed on packaging labels, in standard dosage guidelines, in standard dosage
20 references such as the Physician's Desk Reference (Medical Economics Company or online at <http://www.pdrel.com>) or other sources.

As used herein the term "**antipsychotic**" includes, but is not limited to:

- (a) typical or traditional antipsychotics, such as phenothiazines (e.g., chlorpromazine, thioridazine, fluphenazine, perphenazine, trifluoperazine,
25 levomepromazine), thioxanthenes (e.g., thiothixene, flupentixol), butyrophenones (e.g., haloperidol), dibenzoxazepines (e.g., loxapine), dihydroindolones (e.g., molindone), substituted benzamides (e.g., sulpride, amisulpride), and the like; and
- (b) atypical antipsychotics, such as paliperidone, clozapine, risperidone,
30 olanzapine, quetiapine, zotepine, ziprasidone, iloperidone, perospirone, blonanserin, sertindole, ORG-5222 (Organon), and the like; and others such as sonopiprazole, aripiprazole, nemonapride, SR-31742 (Sanofi), CX-516 (Cortex), SC-111 (Scotia), NE-100 (Taisho), and the like.

In an embodiment, the **"atypical antipsychotic"** is selected from the group consisting of aripiprazole, quetiapine, olanzapine, risperidone and paliperidone. In another embodiment, the atypical antipsychotic is selected from the group consisting of aripiprazole, quetiapine, olanzapine and
5 risperidone; preferably, the atypical antipsychotic is selected from the group consisting of aripiprazole, quetiapine and olanzapine.

As used herein, the term **"depression"** shall be defined to include major depressive disorder, unipolar depression, treatment resistant depression, depression with anxious distress, bipolar depression and dysthymia (also
10 referred to as dysthymic disorder). Preferably, the depression is major depressive disorder, unipolar depression, treatment resistant depression, depression with anxious distress, or bipolar depression. More preferably, the depression is major depressive disorder, unipolar depression, treatment resistant depression and bipolar depression.

As used herein, the term **"treatment-refractory or treatment-resistant depression"** and the abbreviation **"TRD"** shall be defined as major depressive disorder that does not respond to adequate courses of at least two antidepressants. One skilled in the art will recognize that the failure to respond to an adequate course of a given antidepressant may be determined
20 retrospectively or prospectively. In an embodiment, at least one of the failures to respond to an adequate course of antidepressant is determined prospectively. In another embodiment, at least two of the failures to respond to an adequate course of antidepressant are determined prospectively. In another embodiment, at least one of the failures to respond to an adequate
25 course of antidepressant is determined retrospectively. In another embodiment, at least two of the failures to respond to an adequate course of antidepressant are determined retrospectively.

As used herein, unless otherwise noted, the terms **"treating"**, **"treatment"** and the like, shall include the management and care of a subject or
30 patient (preferably mammal, more preferably human) for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or

complications, alleviate the symptoms or complications, or eliminate the disease, condition, or disorder.

As used herein, unless otherwise noted, the term “**prevention**” shall include (a) reduction in the frequency of one or more symptoms; (b) reduction
5 in the severity of one or more symptoms; (c) the delay or avoidance of the development of additional symptoms; and / or (d) delay or avoidance of the development of the disorder or condition.

One skilled in the art will recognize that wherein the present invention is directed to methods of prevention, a subject in need of thereof (i.e. a subject in
10 need of prevention) shall include any subject or patient (preferably a mammal, more preferably a human) who has experienced or exhibited at least one symptom of the disorder, disease or condition to be prevented. Further, a subject in need thereof may additionally be a subject (preferably a mammal, more preferably a human) who has not exhibited any symptoms of the disorder,
15 disease or condition to be prevented, but who has been deemed by a physician, clinician or other medical profession to be at risk of developing said disorder, disease or condition. For example, the subject may be deemed at risk of developing a disorder, disease or condition (and therefore in need of prevention or preventive treatment) as a consequence of the subject's medical
20 history, including, but not limited to, family history, pre-disposition, co-existing (comorbid) disorders or conditions, genetic testing, and the like.

As used herein, unless otherwise noted, the terms “**subject**” and “**patient**” refer to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. Preferably, the subject or
25 patient has experienced and / or exhibited at least one symptom of the disease or disorder to be treated and / or prevented.

The term “**therapeutically effective amount**” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a
30 researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

Wherein the present invention is directed to therapy with a combination of agents, “**therapeutically effective amount**” shall mean that amount of the

combination of agents taken together so that the combined effect elicits the desired biological or medicinal response. For example, the therapeutically effective amount of combination therapy comprising esketamine and a serotonin reuptake inhibitor would be the amount of esketamine and the amount of the serotonin reuptake inhibitor that when taken together or sequentially have a combined effect that is therapeutically effective, more preferably where the combined effect is synergistic. Further, it will be recognized by one skilled in the art that in the case of combination therapy with a therapeutically effect amount, the amount of each component of the combination individually may or may not be therapeutically effective.

Wherein the present invention is directed to the administration of a combination, the compounds may be co-administered simultaneously, sequentially, separately or in a single pharmaceutical composition. Where the compounds are administered separately, the number of dosages of each compound given per day, may not necessarily be the same, e.g. where one compound may have a greater duration of activity, and will therefore, be administered less frequently. Further, the compounds may be administered via the same or different routes of administration, and at the same or different times during the course of the therapy, concurrently in divided or single combination forms. The instant invention is therefore understood as embracing all regimens of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.

As used herein, the terms "**co-therapy**", "**combination therapy**", "**adjunctive treatment**", "**adjunctive therapy**" and "**combined treatment**" shall mean treatment of a patient in need thereof by administering esketamine in combination with one or more antidepressant(s), and further, optionally in combination with one or more atypical antipsychotics wherein the esketamine and the antidepressant(s) are administered by any suitable means, simultaneously, sequentially, separately or in a single pharmaceutical formulation. Where the esketamine and the antidepressant(s) are administered in separate dosage forms, the number of dosages administered per day for each compound may be the same or different. The esketamine and the antidepressant(s) may be administered via the same or different routes of

administration. Examples of suitable methods of administration include, but are not limited to, oral, intravenous (iv), intranasal (in) intramuscular (im), subcutaneous (sc), transdermal, and rectal. Compounds may also be administered directly to the nervous system including, but not limited to,

5 intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and / or peri-spinal routes of administration by delivery via intracranial or intravertebral needles and / or catheters with or without pump devices. The esketamine and the antidepressant(s) may be administered according to simultaneous or alternating regimens, at the same or different

10 times during the course of the therapy, concurrently in divided or single forms.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound or compounds used, the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular patient

15 being treated, including patient's sex, age, weight, diet, time of administration and concomitant diseases, will result in the need to adjust dosages.

One skilled in the art will recognize that, both *in vivo* and *in vitro* trials using suitable, known and generally accepted cell and / or animal models are predictive of the ability of a test compound to treat or prevent a given disorder.

20 One skilled in the art will further recognize that human clinical trials including first-in-human, dose ranging and efficacy trials, in healthy patients and / or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.

As used herein, the term "**composition**" is intended to encompass a

25 product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "**about**". It is

30 understood that whether the term "**about**" is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably

be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.

To provide a more concise description, some of the quantitative expressions herein are recited as a range from about amount X to about
5 amount Y. It is understood that wherein a range is recited, the range is not limited to the recited upper and lower bounds, but rather includes the full range from about amount X through about amount Y, or any amount or range therein.

For use in medicine, the salts of the compounds of this invention refer to non-toxic "**pharmaceutically acceptable salts**." Other salts may, however, be
10 useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid,
15 fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts;
20 and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate,
25 esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate,
30 pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate.

Representative acids which may be used in the preparation of pharmaceutically acceptable salts include, but are not limited to, the following: acids including acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-
 5 (1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, α -oxo-glutaric acid, glycolic acid, hipuric acid,
 10 hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, ($\pm$)-DL-lactic acid, lactobionic acid, maleic acid, (-)-L-malic acid, malonic acid, ($\pm$)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid,
 15 orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebaic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid.

Representative bases which may be used in the preparation of pharmaceutically acceptable salts include, but are not limited to, the following: bases including ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine,
 25 piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidine, secondary amine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide.

Examples

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way
 30 the invention set forth in the claims which follow thereafter.

Example 1 – Retrospective Analysis

We performed a genetic association meta-analysis of treatment resistant depression case control genetic association analyses from two independent

cohorts of European ancestry. Irrespective of the definition provided above, in the meta-analysis described in this Example, cases with treatment resistant depression (TRD) were defined as subjects failing two trials of antidepressant treatment regimens and were drawn either from a Cohort J consisting of

5 patients enrolling in antidepressant clinical studies (n=232) genotyped using Illumina Omni5MExome or from a cohort based on STAR*D study (n=315) genotyped using either Affymetrix 500K or Affymetrix 5.0. Controls were drawn from either the cognitively normal subjects from the ADNI study (n=255) genotyped using Illumina Omni2.5M or the psychiatrically screened healthy

10 controls from NIMH (n=584) genotyped using Affymetrix 500K, respectively. We imputed genotypes based on the reference haplotypes from the 1,000 Genomes prior to meta-analysis to enable direct comparison of variants across the study.

More specifically, for Cohort J, we started with the Illumina

15 Omni5MExome dataset (n~538) comprising subjects from the following studies: (a) RIS-INT-93 (~458 Caucasian subjects including 24 Hispanic subjects); (b) ESKETIV-TRD-2001(n~26, all races); (c) KETIV-TRD-2002 (n~61, all races). Only the patients meeting TRD criteria were defined as cases and only subjects of European ancestry were included in the analysis leading to this invention.

20 Standard SNP-level and subject-level quality control criteria were applied prior to imputation of sites not directly genotyped. SNP-level quality control criteria included 1) Minor Allele Frequency > 1%; 2) SNP-wise genotype missing rate < 5%; 3) Hardy-Weinberg Equilibrium p-value > 1e-06. Subject-level quality control criteria included 1) subject-wise genotype missing rate < 5%; 2)

25 excluded population outliers, cryptic related subject, and subjects with genetically derived gender differing from gender captured in the case report form (CRF) or phenotype file (if exists). The controls for Cohort J were ADNI CN (genotyped using Illumina Omni2.5M, n~281). For the 2nd cohort, the Affymetrix 500K Mapping Array/Affymetrix 5.0 comprised the STAR*D (n~ 1851

30 all races) and NIMH controls (n~ 1727 all races). Similar case definition criteria and similar quality control criteria were applied. The 2 analysis cohorts matched by genotyping platforms were: 1) Cohort J TRD (Omni2.5M using a subset of markers) vs. ADNI CN (Omni2.5M) and 2) STAR*D TRD vs. NIMH

controls screened by Composite International Diagnostic Interview (CIDI-SF) self-report modified to screen for lifetime diagnoses (The Internet-Based MGS-2 Control Samples).

Treatment resistant depression (TRD) was defined as follows: 2

- 5 antidepressant failures (1 retrospective and 1 prospective failure for RIS-INT-93; 2 prospective antidepressant failures for STAR*D; or 2 retrospective antidepressant failures for ESKETIV-TRD-2001 & KETIV-TRD-2002).

Prospective antidepressant failure was defined by using HAM-D-17 clinical scale for patients with percentage of change in HAM-D-17 score greater than
10 -50%. The minimal treatment length was 6 weeks for RIS-INT-93 and 8-12 weeks for STAR*D.

The associated markers in the meta-analysis (directly genotyped marker $P=8.51 \times 10^{-7}$; imputed marker $P=3.56 \times 10^{-8}$ passing the conventional genome-wide significance threshold ($P=5 \times 10^{-8}$)) were located in a 50kb interval (3p24.3)
15 in chromosome 3 with only unannotated spliced EST reported, within a linkage interval implicated in a linkage meta-analysis (3p25.3-3p22.1). The genetic data from each TRD sample independently supported this association, with uncorrected significance levels of $P=2.37 \times 10^{-5}$ for the STAR*D cohort and $P=0.005$ for the Cohort J. (See Table 1 and Table 2, below). Minor allele G
20 was determined to occur at a lower frequency in TRD than in a generally healthy population. Patients with each copy of the G allele had ~0.7x lower odds of exhibiting treatment resistant depression (TRD). rs4306882 was directly genotyped in Cohort J; and imputed in the STAR*D cohort.

25

Table 1

Cohort	CHR	SNP	BP	A1	A2
Cohort J vs. ADNI CN	3	rs 4306882	21062584	G	T
STAR*D TRD vs. NIMH Controls	3	rs 4306882	21062584	G	T
Cohort	FRQ	INFO	OR	SE	P
Cohort J vs. ADNI CN	0.386	0.9777	0.6754	0.14	0.005078
STAR*D TRD vs. NIMH Controls	0.3771	1.0139	0.5249	0.1525	2.37E-05

Abbreviations in Table 1 are as follows:

CHR Chromosome code, if map file specified

	SNP	SNP code
	BP	Base-pair position, if map file specified
	A1	Allele 1 code
	A2	Allele 2 code
5	FRQ	Frequency of A1, from dosage data
	INFO	R-squared quality metric / information content
	OR	Odds ratio for association
	SE	Standard error of effect estimate
10	P	p-value for association tests

Table 2:

For Chromosome 3, SNP rs4306882 at Base pair position 21062587

A1	F A	F U	A2	CHISQ	P	OR
G	0.3378	0.4321	T	10.16	1.43E-03	0.6703

Abbreviations in Table 2 are as follows:

	A1	Minor allele name (based on whole sample)
15	F_A	Frequency of this allele in cases
	F_U	Frequency of this allele in controls
	A2	Major allele name
	CHISQ	Basic allelic test chi-square (1df)
	P	Asymptotic p-value for this test
20	OR	Estimated odds ratio (for A1, i.e. A2 is reference)

The sequence ID for SNP rs4306882 is as follows:

SEQ. ID. 1:

GGATGCCACA TGCAGATGTA TTTTCTTTGG TCCACATATG GCATCCAACC CATGAGCTAT
 25 AGAAAAATATG GATTTCCTGGA TTTCTTTGAA ACACTGAAAG ATCTGGAGCC TCTGGGCCAC
 TGTTACTGGA TAATAGCAAC AGCCTGAGTG TTTGCATTTA TAACCTGTAA TAAGAGACGC
 ATGTCTCCTT GCTGCTCAAG TTATAGATCT GACAGCCCAG GATATGATTA ATCAGAGCTC
 AGGGCTCAGG AAGCCATTCT CCACATCTGG CAGAGCCCGA CAAAATCTTT GCAATCAGAT
 TAACGAAGCA GTGACATGAT GTTCTATTAG TGGGGGCATG GACATGCAAA ATCATTATGC
 30 AGAACAATTC ATTATCATAG CTGACCATGT ACAGGGTTTT AGCTGCATGT CGATGTGGCA
 CAGCTCACTG AAGATGCATG GATAAACGCT GTGGCTAAGG CATTGTGAGA GCAATTGGTA
 GGAGCTAGAA AGCTAGCTCT
 K
 AAGCCAAGCT AGAAGAGAAA CACAGTTCTG GGATCACCAT TCATTTTGCT CTTTCTGGGT
 35 CCTTTIATAT CTGCTTTAGC AAGGTACCTG CTTTAACAAT GTACATTCTT GCATGAATGT
 TTTCTTTTCT CTTTCAATTC TTCTTCCATC CTGGTGTTTA GGATATCACT GGGGTGGGAT
 AGTGGGAGAG GTGGCAGTTT TATTTTGTTT TTAAGTATAT CAGTTCTCCT TTTTGATATC
 AGCTTTTCTT TTTGAATAGT CCAGGATATA CTTGCCTCTC AAGCAGCTTT TTTTCTCTC
 AAAGCCAGTT CTTCTTATGC AACAGACTTA CTATATCATT CACAGATTGT ACCATGAGGG
 40 TTCACCTTCT TGCACCTATA TTAGGCCACA ACCTCTAAGC ACAAAGGTCT TTTCATGACT

GTTTATTGAA ATACCCAGCA AGAATTTTCA TCAGACAGAG TTTTAGTCAT GCTTTAACTC
 TGCAACTTAT TAAAATGGGA
 >gnl|dbSNP|rs4306882|allelePos=501|totalLen=1001|taxid=9606|snpclass=1
 |alleles='G/T'|mol=Genomic|build=138

5

SNP rs4306882 was further determined to be in linkage disequilibrium (LD) with an array of the SNPs in the close by genomics region as shown in Table 3, below.

In certain embodiments, the present invention is directed to methods (as described herein) wherein the patient's genotype is determined at any single SNP listed in Table 3 below, alone or in combination with a determination of the patient's genotype at SNP rs4306822. In certain embodiments, the present invention is directed to methods (as described herein) wherein the patient's genotype is determined at any subset of SNPs selected from the list in Table 3 below, alone or in combination with a determination of the patient's genotype at SNP rs4306822.

Table 3

Chromosome 2 (CHR)										
BP	SNP	A1	A2	N	P	P(R)	OR	OR(R)	Q	I
119536884	rs1551133	C	A	2	2.85E-07	1.68E-04	0.4418	0.4392	0.1699	46.91
Chromosome 3 (CHR)										
BP	SNP	A1	A2	N	P	P(R)	OR	OR(R)	Q	I
21061286	rs869495	G	A	2	5.54E-07	0.0006712	0.5941	0.5898	0.1367	54.84
21061473	rs869494	T	A	2	6.68E-07	0.001478	0.5967	0.5914	0.1129	60.21
21062584	rs4306882	G	T	2	8.51E-07	4.85E-05	0.6019	0.5997	0.2233	32.57
21063058	rs4465961	T	C	2	8.85E-07	0.000537	0.5939	0.5897	0.1513	51.43
21063578	rs7625772	T	G	2	6.24E-07	0.00096	0.5947	0.5897	0.1263	57.21
21063804	rs7633632	G	A	2	6.21E-07	5.14E-06	0.5963	0.5954	0.2733	16.68
21063919	rs7612422	C	G	2	1.43E-07	1.64E-07	0.5804	0.5803	0.3149	1
21067747	rs7646153	G	C	2	8.42E-07	0.0004885	0.5984	0.5947	0.1539	50.81
21069166	rs1391144	G	A	2	9.95E-07	9.95E-07	0.6022	0.6022	0.3234	0
21072614	rs2047387	G	A	2	2.04E-07	2.04E-07	0.5822	0.5822	0.3415	0
21077201	rs6769146	G	A	2	4.83E-07	4.83E-07	0.5911	0.5911	0.3302	0
21077685	rs6550565	G	C	2	7.97E-07	6.70E-06	0.5866	0.5856	0.272	17.12
21081507	rs56871503	C	T	2	6.99E-07	0.0004664	0.5965	0.593	0.1525	51.14
21085039	rs11295121	TG	T	2	9.11E-07	9.11E-07	0.6007	0.6007	0.3262	0

21087408	rs4858288	A	G	2	3.76E-07	3.76E-07	0.5893	0.5893	0.3634	0
21088048	rs1391138	G	T	2	2.82E-07	2.82E-07	0.5852	0.5852	0.3252	0
21088878	rs9881998	C	T	2	5.63E-07	3.08E-05	0.5918	0.59	0.228	31.2
21089069	rs9811079	G	A	2	2.62E-07	2.62E-07	0.5843	0.5843	0.3787	0
21093953	rs13097458	C	A	2	9.97E-07	9.97E-07	0.597	0.597	0.389	0
21097393	rs973870	C	A	2	6.85E-07	0.0004483	0.5957	0.5918	0.1531	51.01
21099489	rs7652147	G	A	2	7.14E-07	0.0004306	0.5958	0.5921	0.1551	50.52
21099939	rs141786492	TTTTC	T	2	4.54E-07	0.0008831	0.5822	0.5771	0.1245	57.63
21100108	rs7644744	A	G	2	6.62E-07	0.000343	0.5943	0.5908	0.1612	49.05
21102620	rs985536	G	A	2	6.54E-07	6.54E-07	0.5921	0.5921	0.4025	0
21106260	rs9865061	T	A	2	2.28E-07	8.84E-05	0.58	0.5773	0.184	43.35
21106404	rs11128983	G	A	2	5.11E-07	5.42E-05	0.589	0.5868	0.211	36.07
21107235	rs9850499	C	T	2	3.45E-07	2.87E-05	0.5798	0.5779	0.221	33.23
21107330	rs71935600	CAG	C	2	2.39E-07	0.0001414	0.5709	0.5676	0.1714	46.55
21108963	rs200621794	AAAG	A	2	3.56E-08	3.56E-08	0.5581	0.5581	0.3527	0
21108964	rs67575809	AAG	A	2	2.80E-08	2.51E-07	0.5549	0.5546	0.2812	13.9
21109078	rs7372757	G	A	2	2.25E-07	2.25E-07	0.5801	0.5801	0.7251	0
Chromosome 4 (CHR)										
BP	SNP	A1	A2	N	P	P(R)	OR	OR(R)	Q	I
148693230	rs2164527	C	T	2	4.17E-07	4.17E-07	0.451	0.451	0.6757	0
Chromosome 11 (CHR)										
BP	SNP	A1	A2	N	P	P(R)	OR	OR(R)	Q	I
86572384	rs12285365	G	A	2	4.43E-07	4.43E-07	0.5116	0.5116	0.6906	0

Abbreviations in Table 3 above, are as follows:

5	CHR	Chromosome code, if map file specified
	BP	Base-pair position, if map file specified
	SNP	SNP code
	A1	Allele 1 code
	A2	Allele 2 code
10	N	Number of valid studies for the SNP
	P	p-value for association tests
	P(R)	Random-effectsmeta-analysis p-value
	OR	Odds ratio for association
	OR(R)	Random effects OR estimate
15	Q	p-value for Cochrane's Q statistic
	I	I ² heterogeneity index (0-100)

Thus, we believe that we have identified a candidate genetic marker for TRD with association p-value passing genome wide significance using a relatively small sample size by GWAS standard. The identification of genetic

markers associated with resistance to biogenic amine-based antidepressant drugs holds the potential to guide researchers toward unprecedented targets in the discovery of novel treatments for TRD.

While the foregoing specification teaches the principles of the present
5 invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

10

We Claim:

1. A method for the treatment of depression comprising:
Step A: genetically testing (or genotyping) a patient suffering from depression to determine the patient's genotype at rs4306882;
Step B: (i) wherein if the patient carries the G allele at SNP rs4306882, esketamine is administered intranasally to said patient at a dosage of about 28 mg to about 32 mg, one to three times per week for up to eight weeks, or
(ii) wherein if the patient carries the T allele at SNP rs4306882, esketamine is administered intranasally to said patient at a dosage of about 28 mg to about 32 mg, two to five times per week for up to eight weeks.
2. The method of claim 1, wherein the depression is treatment resistant depression (TRD).
3. The method of claim 1 or claim 2, wherein if the patient carries the G allele at SNP rs4306882, esketamine is administered at a dose of about 28 mg.
4. The method of claim 1 or claim 2, wherein if the patient carries the T allele at SNP rs4306882, esketamine is administered at a dose of about 32 mg.
5. A method for predicting whether a patient suffering from depression is genetically predisposed to poorly respond to antidepressants which block the reuptake of monoamine neurotransmitters, comprising genotyping said patient to determine whether the patient has a G allele or a T allele at SNP rs4306882.
6. The method of claim 5, wherein the depression is treatment resistant depression.

PRD3345WOPCT_SeqListing.txt
SEQUENCE LISTING

<110> JANSSEN PHARMACEUTICA NV

<120> METHOD FOR THE TREATMENT OF DEPRESSION

<130> PRD3345WOPCT

<140>

<141>

<150> 62/036,896

<151> 2014-08-13

<160> 35

<170> PatentIn version 3.5

<210> 1

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 1

ggatgccaca tgcagatgta ttttctttgg tccacatatg gcatccaacc catgagctat	60
agaaaatatg gatttctgga tttctttgaa acactgaaag atctggagcc tctggggccac	120
tggtactgga taatagcaac agcctgagtg tttgcattta taacctgtaa taagagacgc	180
atgtctcctt gctgctcaag ttatagatct gacagcccag gatatgatta atcagagctc	240
agggctcagg aagccattct ccacatctgg cagagcccga caaaatcttt gcaatcagat	300
taacgaagca gtgacatgat gttctattag tgggggcatg gacatgcaaa atcattatgc	360
agaacaattc attatcatag ctgacctgt acagggtttt agctgcatgt cgatgtggca	420
cagctcactg aagatgcatg gataaacgct gtggctaagg cattgtgaga gcaattggta	480
ggagctagaa agctagctct kaagccaagc tagaagagaa acacagttct gggatcacca	540
ttcattttgc tctttctggg tccttttata tctgctttag caaggtaacct gctttaacaa	600
tgtacattct tgcatgaatg ttttcttttc tctttcaatt cttcttccat cctggtgttt	660
aggatatcac tgggggtggga tagtgggaga ggtggcagtt ttattttggt ttttaagtata	720
tcagttctcc tttttgatat cagcttttct ttttgaatag tccaggatat acttgccctc	780
caagcagctt ttttttttct caaagccagt tcttcttatg caacagactt actatatcat	840
tcacagattg taccatgagg gttcactttc ttgcacctat attaggccac aacctctaag	900
cacaaaggct ttttcatgac tgtttattga aatacccagc aagaattttc atcagacaga	960
gttttagtca tgctttaact ctgcaactta ttaaaatggg a	1001

<210> 2

<211> 601

<212> DNA

<213> Homo sapiens

<400> 2

tagatttttc aaactttatt atttcttagg atgtgtatag ttggttatth tgcttaacta	60
ctttaactat tgataaatta atctgtaaaa aaaagaaaga ttttatcggt catgtttatc	120

PRD3345WOPCT_SeqListing.txt

tctggatttt	tgtgagcaac	ttaaaagatg	aaaggtgaaa	ggtaaaaggt	tttgaaatat	180
tgtgatgaat	tatcataatt	aaagtttata	tcgttagtaa	gaactaaaag	tatatgtcta	240
tgcaccctaa	ctcataatat	gtactattca	cagtctatat	atacacaaag	aaaaacaaac	300
mattactaaa	tgccaattac	atgccaacct	tactggaagc	tcttagcacc	cattaactca	360
tttaatccta	agaacaatcc	attgttttaa	gtatgattta	tttcttcaaa	ttatagatgg	420
taaaactaac	cctaaacatg	ttgcagcata	aacagttgcc	taatttatta	cttttagaaa	480
accatgacac	caagatttaa	tcccacttat	tttatgaaag	tcattgaaac	agaaaccaat	540
ttctcaataa	taccctcata	aacatatgac	tttgaaatac	tctaaaaata	ttctagtttt	600
t						601

<210> 3
 <211> 1103
 <212> DNA
 <213> Homo sapiens

<400> 3						
atgaccagca	actaccagaa	gctacaggag	tggcatgcaa	cagactaccc	ttacaacctc	60
agaaggagca	aaccctatca	acatcttgat	tttggccttc	tcgcctccag	aattgtgaca	120
gaacaaatta	ttgttatttt	aagccattca	gtttgtcatc	ttttgttaca	gcagccctag	180
acagtcaggg	tatgctgaac	agctgtaacc	aacacaccca	agatgtgtaa	tggctccaac	240
acaaccaaag	tttacagtaa	cagtccaagg	ccaagttcca	ttggtgggca	cctctactgc	300
acacggtcac	ttagacatcc	aagctaacag	agggtttgcc	atctttaaca	gtgggtttccc	360
aagactgcct	tggtcctacc	attctagtcc	atgggaacag	aaaacagaag	aggtttgata	420
agctggccaa	aaatggctat	atcacttctg	gtcacatttt	cttgaagaga	acttagtaat	480
atggctctac	tcagttgcaa	tagggacata	tgcaatatgg	tgcagctgga	ggagagctag	540
tgattcttct	gmaatgatga	aagctgctat	ttgaaaaggg	ggcagtgaga	gagcttattt	600
ccaggaatgc	aaaagccagg	gagttagaga	aacagtgtcc	aactcttcca	ccagtcttga	660
ggataatgca	atttaagaga	tggatcaggt	gaaggctttt	gaaaaaaaga	atagaaaact	720
agggcaaagc	aagggcccta	ggaagatggc	aagcatcctg	caaggtttag	ctattagaaa	780
actcatggga	atgccctatt	attatatcca	gatgttctaa	ggaaatttca	acccaactct	840
gccccaaagg	ataggctcca	gaaagaatca	tcctgcttac	agcaccaggc	ctctgattca	900
aagaacttga	gagagaataa	aattagcaca	gcatagccag	aactgaagtc	ctgtaaggac	960
ccccataaag	tagacatcag	gacccgagag	attcatcaaa	ggagaccag	tttgtttaatt	1020
ggtttcctgg	taaacagtca	agaacctggg	tttggtgat	tcaggagtca	gatagagctg	1080
ggaataaatc	ctcctttatg	gct				1103

<210> 4
 <211> 1001
 <212> DNA

<213> Homo sapiens

<400> 4

tctgttccct ggtgactgtt tctgctctcc tgaccactgc acatctgtga catctgtctca	60
gctaaagtta gtggcttcta tctgttgcct gggtctagac ttcgtgtttg gcttcaactt	120
atgctttgtt tctaaaatct caaatctcct gggtttttac ttctagccct gttctctacg	180
gttcaagacc agcccagctg atattcagct aaaaataaca ttgtgtaaca catagtttat	240
tacataactt agtatttaat agtcaatgct aattgaatac agaaaagtga gatttaaagt	300
cggtttagat aacacactgg tagacaaacc cagaagaggg gagcagaatt tatgtacaat	360
atgactcttt atatgtttgt ttttctttca aattatgata agttctcatc aatgtaaaag	420
gccattatth tactgtttgt agtggtttca gcatctctga ggtgggaaac agtgggtact	480
gctgcttgaa aatgaaagaa ytaagtgtc actgtgcacc tcactctgtg gaagaacttt	540
atagactttt ttcattggagt acctcaaaca aaaggaagta ctgatacttg gaaaacatta	600
gtcgtgaagat gatatagatg cttctaatta accataggaa tcaaattatc tatcattttc	660
ttgagtttct acattgtgct aggccttcta ctaagaacta taaagatgac attaataact	720
tacaataatt tccaagatag gttttagaat tttagtctat cacagttaat ggaattggga	780
cctagaaaac tcacatagag tgtagtgaat ccaggattta atcaaagcca agttagagag	840
gttccttata ccatagaggc tccaaggata ccacctacct ttcagggtcac ataacttcag	900
aaggaactga actaactaaa gtgagccttg attaaagccc ataataaaca gaggtttgag	960
gtaaatgcag aaatttcaag taagagaaga aactaattgt t	1001

<210> 5

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 5

ttccctttct ataggtaagc aaaatttaat ttacagaggt gaagtgatct gtttataatt	60
gtatacctag ggagtagaaa agactaaatg ctgatctaag ccctaggact tatggtcatt	120
tcagcaaccc taaagtctc ataaacttcc ttctatgtta atacaacttg tttgtcttct	180
aatgtcatct gttccctggg gactgtttct gctctcctga ccactgcaca tctgtgacat	240
ctgctcagct aaagttagtg gcttctatct gttgcctggg tctagacttc gtgtttggct	300
tcaacttatg ctttgtttct aaaatctcaa atctcctggg tttttacttc tagccctgtt	360
ctctacgggt caagaccagc ccagctgata ttcagctaaa aataacattg tgtaacacat	420
agtttattac ataacttagt atttaatagt caatgctaata tgaatacaga aaagttagat	480
ttaaatgcgg tttagataac wactggtag acaaaccag aagaggggag cagaatttat	540
gtacaatatg actctttata tgtttgtttt tctttcaaat tatgataagt tctcatcaat	600
gtaaaaggcc attattttac tgtttgtagt ggtttcagca tctctgaggt gggaaacagt	660
gggtactgct gcttgaaaat gaaagaacta agtgctcact gtgcacctca ctctgtggaa	720

PRD3345WOPCT_SeqListing.txt

gaactttata gacttttttc atggagtacc tcaaacaaaa ggaagtactg atacttggaa	780
aacattagtc gtaagatgat atagatgctt ctaattaacc ataggaatca aattatctat	840
cattttcttg agtttctaca ttgtgctagg ctttctacta agaactataa agatgacatt	900
aataacttac aataatttcc aagatagggt ttagaatttt agtctatcac agttaatgga	960
attgggacct agaaaactca catagagtgt agtgaatcca g	1001

<210> 6
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 6 ttggtaggag ctagaaagct agctctgaag ccaagctaga agagaaacac agttctggga	60
tcaccattca ttttgctctt tctgggtcct tttatatctg ctttagcaag gtacctgctt	120
taacaatgta cattcttgca tgaatgtttt cttttctctt tcaattcttc ttccatcctg	180
gtgttttagga tatcactggg gtgggatagt gggagagggt gcagttttat tttgttttta	240
agtatatcag ttctcctttt tgatatcagc ttttcttttt gaatagtcca ggatatactt	300
gcctctcaag cagctttttt ttttctcaaa gccagttctt cttatgcaac agacttacta	360
tatcattcac agattgtacc atgagggttc actttcttgc acctatatta ggccacaacc	420
tctaagcaca aaggctcttt catgactgtt tattgaaata cccagcaaga attttcatca	480
gacagagttt tagtcatgct ytaactctgc aacttattaa aatgggagca ctttatataa	540
tttgcttaac tcttctaagc tttagttcct tcttcctaaa aataggagtt gtaggaagaa	600
agatgagtgg gtcctgtttc atttggttac ttttacatta aaatgcaatg aatctctatg	660
ggtagctctga acttgtgact ggctaggtaa gccagatttc agtgtgcttc acagacctgg	720
tgaccttggga cttggaaggg agaaggacac aagatgtctc actgaggcct tttggagtaa	780
gctattctcc aatatacatt tcttacagga tgcttgtcta cttactcatt tggtcactat	840
ccttaagtgc atagctcttt ataggaaaca atttcaatag tggaagagaa acgataagtt	900
tcattcacat acaaacctc aactcaacca atcaatgttt ataaagcaca ctcatcgtct	960
ttgaaaaaag atatcagtgt cacagggtcag gttccccaga a	1001

<210> 7
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 7 aatgggagca ctttatataa tttgcttaac tcttctaagc tttagttcct tcttcctaaa	60
aataggagtt gtaggaagaa agatgagtgg gtcctgtttc atttggttac ttttacatta	120
aaatgcaatg aatctctatg ggtactctga acttgtgact ggctaggtaa gccagatttc	180
agtgtgcttc acagacctgg tgaccttggga cttggaaggg agaaggacac aagatgtctc	240
actgaggcct tttggagtaa gctattctcc aatatacatt tcttacagga tgcttgtcta	300

PRD3345WOPCT_SeqListing.txt

```

cttactcatt tggtcactat ccttaagtgc atagctcttt ataggaaaca atttcaatag      360
tggaaagagaa acgataagtt tcattcacat acaaaacctc aactcaacca atcaatgttt      420
ataaagcaca ctcatcgtct ttgaaaaaag atatcagtgt cacaggtcag gttccccaga      480
aagtgcactc tgaagtaaaa kctcatatat ggtaagttta ttaagaaatg ctcttcagat      540
caatactctt ggaataaaaa ggaaggaatc aggattatga agaaaagctt tggctgtgat      600
gcaatctcaa cacaatTTTT acccaatccc acagataaaa atagctggga ttactgttta      660
gagtgggtga agagcaagcc ttatactcc aactgacaa gttgttaatt gtggctacct      720
ctaagaggaa gagtctcctt taaagaggca actctatcta gcccatggca atttgaagtg      780
tgggtgggaa ccgagaagct aaataaatca attttttgct tttcctcagt acagatatTT      840
ccccTTTTga agccacctag agcattgcgt gtaccactta cttttgcatg atgctttata      900
ttcacaaaac attatctcac atgcctccca tgatctttca tgaagcagat aaagcacata      960
ttatttagag aataagaaac aaaacttttc agacttttcc c                               1001

```

<210> 8

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 8

```

acacaagatg tctcactgag gccttttgga gtaagctatt ctccaatata cttttcttac      60
aggatgcttg tctacttact ctttgggtca ctatccttaa gtgcatagct ctttatagga      120
aacaatttca atagtggaag agaaacgata agtttcattc acatacaaaa cctcaactca      180
accaatcaat gtttataaag cacactcatc gtctttgaaa aaagatatca gtgtcacagg      240
tcaggttccc cagaaagtgc actctgaagt aaaatctcat atatggtaag tttattaaga      300
aatgctcttc agatcaatac tcttggaata aaaaggaagg aatcaggatt atgaagaaaa      360
gctttggctg tgatgcaatc tcaacacaat ttttaccxaa tcccacagat aaaaatagct      420
gggattactg tttagagtgg gtgaagagca agcctttata ctccacactg acaagttggt      480
aattgtggct acctctaaga rgaagagtcc tccttaaaga ggcaactcta tctagcccat      540
ggcaatttga agtgtgggtg ggaaccgaga agctaaataa atcaattttt tgcttttctt      600
cagtacagat atttcccctt ttgaagccac ctagagcatt gcgtgtacca ctacttttg      660
catgatgctt tatatttcac aaacattatc tcacatgcct cccatgatct ttcatgaagc      720
agataaagca catattatTT agagaataag aaacaaaact tttcagactt ttcccaatga      780
ttgggaaaag tagcctttaa caaataaaaa tctctgccgg acttagcttt cttttaaaca      840
aaataggggt gtaaaataac ttacctgcct actatttaat ccagcacta ggatctatga      900
atgtgtacct tgcacagatt tatgtgtttg ctaagtggag gagacagcca cagcatctgt      960
atcctgtgga ctactgttcc agggctctat acactgcccc a                               1001

```

<210> 9

<211> 1001

PRD3345WOPCT_SeqListing.txt

<212> DNA

<213> Homo sapiens

<400> 9

taggaaacaa	tttcaatagt	ggaagagaaa	cgataagttt	cattcacata	caaaacctca	60
actcaaccaa	tcaatgttta	taaagcacac	tcctcgtctt	tgaaaaaaga	tatcagtgtc	120
acaggtcagg	ttccccagaa	agtgcactct	gaagtaaaat	ctcatatatg	gtaagtttat	180
taagaaatgc	tcttcagatc	aatactcttg	gaataaaaag	gaaggaatca	ggattatgaa	240
gaaaagcttt	ggctgtgatg	caatctcaac	acaattttta	cccaatccca	cagataaaaa	300
tagctgggat	tactgtttag	agtgggtgaa	gagcaagcct	ttatactcca	cactgacaag	360
ttgttaattg	tggctacctc	taagaggaag	agtcctcctt	aaagaggcaa	ctctatctag	420
cccatggcaa	tttgaagtgt	gggtgggaac	cgagaagcta	aataaatcaa	ttttttgctt	480
ttcctcagta	cagatatttc	sccttttgaa	gccacctaga	gcattgcgtg	taccacttac	540
ttttgcatga	tgctttatat	ttcacaaaca	ttatctcaca	tgcttcccat	gatctttcat	600
gaagcagata	aagcacatat	tatttagaga	ataagaaaca	aaacttttca	gacttttccc	660
aatgattggg	aaaagtagcc	tttaacaaat	aaaaatctct	gccggactta	gctttctttt	720
aaacaaaata	ggggtgtaaa	ataacttacc	tgcttactat	ttaatcccag	cactaggatc	780
tatgaatgtg	taccttgcac	agatttatgt	gtttgctaag	tggaggagac	agccacagca	840
tctgtatcct	gtggactact	gttcaggggc	tctatacact	gccccacact	accctgatag	900
cactgaggtc	aatgatgggt	ctattgcctg	agactgtaga	aaagacaagc	acaaaagcat	960
gtgaaagaac	aaggatacaa	tctgagggaa	tgtttccaga	g		1001

<210> 10

<211> 1614

<212> DNA

<213> Homo sapiens

<400> 10

acctcttatg	tctttaattt	cctcctttca	agttttattt	gccagaccat	attctccttt	60
taaatgttag	aaatgtaaat	gttaaaatgc	cttccattcc	atatacttta	agtaggtgat	120
ttcatctgac	ccttaaattt	cctctcttat	caattcctcg	atgattcatc	tgagctttct	180
tgctgatgtc	tcctgaaaat	agatgtccag	cccgagtttt	acaagcctac	tccatatttg	240
tatatctacc	cacctaataa	atatattcac	ttgaatgtct	aatgcacatt	ttaaacttaa	300
catgaccaa	atcgattttt	ttcctaaaat	tccactccat	ccatagcctt	gctcaactca	360
gttaatagca	attcaatatt	ttcaattggg	gtaattcttg	actccccacc	tctcaaacca	420
cattgtccag	tctctcaaat	ccaattgctt	gtaacttcag	aataaatcta	taacatgatc	480
gtatctcgcc	aactccatgg	ctactgtctt	agtcttaagc	accataattg	ctgaaaatta	540
ttgcaatagc	ttcctaattg	gtttttctgc	ttctaccgaa	gttatattaag	cagctgtgcc	600
agtttttctg	agacctacca	ggttttatca	ctgaaagtca	tgtgtctcag	aaaacccttc	660
attctcaaga	aaactgggac	atctgctatg	tactctcaag	acaacatgta	gagttgttgt	720

PRD3345WOPCT_SeqListing.txt

ttaaaaaatat	atcaaaccat	atcactcttc	taatscaatc	cttcattgat	tccctacttc	780
actcagggta	aaaactaaca	tccttacaat	ggccttcaag	accatattca	atgtagtcac	840
tgtttcctct	gcttgtctga	cttctataac	tctccttctc	agtttctagc	cacggtgact	900
tatactgttt	gagcccaggt	gcccttctcc	tttggggctc	ttgcactggg	tcttcctctc	960
gggactctca	ccctctagat	atatacatgg	ctcacacctc	atttatttca	gagcttttct	1020
catacttcaa	cttctcaatt	atcctcattc	tggccatctt	aaatagtatt	acaatgtcca	1080
ctctcagaac	tctgaatcct	cagtgtattc	ccaatattca	gaacagttcc	tagctcaata	1140
aatattgagt	acctaataat	tgttaaataa	acaaatgaat	ggcttcattt	cccatccaca	1200
tatatgggtg	gttttctctc	tctccctccg	aatatatctc	ccttttggtt	tattttcctc	1260
atgattgaga	ttgggtgccct	tataaacaag	actgcagaga	gctagtcccc	tttactgttt	1320
gaggacatct	ggctagatgg	tgacatctat	gagaaagggg	gacctacca	gccactgaat	1380
ctcccagcga	cttctatttg	gacatcccag	cctccagaac	tgtgagaaat	aaaatgctat	1440
tatgagttac	ccagcctata	gtattttgtt	atagcattcc	aaatgggcta	agatatatat	1500
gtgtgtgtgt	gtgtgtgtgt	gcgtgtgtgt	gtgtgtatgt	attccaaatg	gactaagata	1560
tgtaaaagtg	tgtgtgcata	tgtgtatgtg	tattccatgt	gtagatggta	aatg	1614

<210> 11
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 11	
ttatagcaat	tcaaattggac taagatatgt gtgtatataa aagcatgtgt acatgtgtat 60
atgtgtgtgt	gtgtgtgtgt accccacgtg tagatggtaa ataaagctct tcttatgttt 120
attatatata	cagtcgtgca tcacttaaca acaagtgtat gttgagaatg tatttttagg 180
ctatttcact	gttcacaaaa cttcataggg tgcacttaac acaaaccttg actacatagc 240
ctactataca	cctaggataa atggcatagc ctattgctcc taggctacaa acctgtacag 300
tacaccatgt	tactgtactg taggtaattg taacaagatg gtgtttgtgt atctaaacat 360
atctaaacat	agaaaagggtt aaaatatggg attataattt tatgaaactg ccattatata 420
tgaagtttat	tcttgatcaa aacattgtta tgcagtgcac gtattatatg tatgtataag 480
gtatatatgg	tatataatgt dtatgtatat atggatatatt ttatatatgt ttatacatat 540
accgagagaa	gatatataca tgtgtggggg tatatgtaaa tacctcctcc tatgcagaca 600
tctcttaaca	gttcacatat ctaagtattt ctgccttctt aactctacca ccagggcatc 660
ctattggcat	ttcagactcg atttattcaa aatttagttc attgtctttc taagaaagcc 720
acactttctc	cagaatgact atattttatg tctaattaca caaggtagga atttgaattc 780
cacatattat	acccccttct ccatgatattt ctttatctgc aatcctacca cttctgaata 840
tatggaatct	ctttacttcc ctccacctat gttattatcc atgaccacag tattatttct 900

PRD3345WOPCT_SeqListing.txt

cagcaggagg ctgttcctaa ctgactttca cattttctct ctctcctctc ttaaattccat 960
 ttttcaccct gaggttaagct ggaacacaaa aatataattg t 1001

<210> 12
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 12
 gagttactgt gtttttcttg aagcaaacaa agatttgaga atgtagacta tgtgtgctgg 60
 gggctccatg tccttttcga tttctttatg cattcttgag tagaaaaaag cagagtgcctt 120
 gtgttttttt tctagttaat tctggctctg atctgtgaca tcctctgaat ttaggaagaa 180
 gccatctttt atcccactta tggcacctca gggtcacatt gctgggtccag atgcaaaaca 240
 cagtcaatct ttgatttatc cccaaacata actcacataa agcattatta tataaaatag 300
 aatttactga agattttttt gtaatgctga atgtgtgctt ttcattgttaa acatttatgt 360
 tgaagacaca ttgtttatta gtagttgggt gttttttaga gtctctgaaa tttctgtgga 420
 catagtctct agcctctgct ctacctttcc ctctcttctc tgctctccat ccctttccaa 480
 gtttctatct cttatctaga rcaatttagc tttcttctct tctttatctt cctctcatct 540
 ctgtttatac aaaaatatct ttttaattat ggatgattct tagctatctt ttgataccag 600
 gtattaaata ttggtatggt tttgtattat tttgttttgt cttgctgtat gtgtctaaca 660
 atatgcattt tcctagatca gaaccattca gtataaatat aatgtgagtc atatgtttac 720
 ttttgcatct tctaatagtc acattaatga attaaaaaaa ctcaggtata acaaacatta 780
 attgtatatt ttatttaacc aagtaagttt aaaatattat ctcaagatgc aaccaatata 840
 aaaattattg agatatttaa tctttttcat tgtactaagt ctttataatc tgggtgtgtat 900
 tttatacctc cagcccatct gaattcagat gctaaatttt cattggatat gcttgatctc 960
 tctttagatt tcataaaatt tgtagtggaa ttattagact t 1001

<210> 13
 <211> 4205
 <212> DNA
 <213> Homo sapiens

<400> 13
 ataaaattaa tagcgttaaa tgctcatgat gtgccattac gtggacttta acaatatttt 60
 gatgacatta cacttcacat aacatccttc ctaaaagaca aaattattaa ttagataata 120
 gctttaaatt ttaaaactag ataaactaac cccttccccc agtaggtttt gttatttttag 180
 aattgtgcag ggcttttagta ttttttcac tttttttttt aattgacaga taaaaattgt 240
 gtatatttgg tgtaaataag atgttttgaa atacatatac attctggaat ggctagatca 300
 acttaattaa catatgcagt acctcacaaa catcatttat ttgaggcaaa taaaattccat 360
 tctgttagaa ttttcaagt taagcacatt gctgttaact ttaatcactg tgttgcacaa 420
 tagatctcct agattcatcc atgttatcat aaatgacaga attttcttct ttttaaggct 480

PRD3345WOPCT_SeqListing.txt

gaataatagt gcatatgcgt atatatgtat gtataaataa aacgtttttca ctatccgttc	540
atccattgat agacacttag gttgattcta gaatatgccca caatggacaa tggagtagag	600
ctgtctctac agatggattt tctttctttg gctatatacc aagaaatgaa atgtctagat	660
catgtggtaa ttctgttttt taattttttt acaactcttc ctaacagttt tccataatag	720
ctgtactaat ttacatttcc acaaacaatg tacaagaatt ccctttcctc tacatcctaa	780
tacttggtat cttttgtttt tctgataaca gccattctga aagggtgtgag gtaatgtctc	840
attgtagttt tgatttgaat tccctgacga ttagtggttt taagcatttt tcatatacca	900
ttggccattt gtatgtcttg agaaacatct attaagatcc tttgccagta ttttaattag	960
attattttcc ttgctattga attctttaag atctttattt tttttgtgta tacatagata	1020
catatattat taacgttgat tatttatctg taaatttatt ttataattt caacttttat	1080
tataggttaa agactacacc tgcaggtttg ttgcatgagt aaattcctga ttctgaggct	1140
tggagttaca atgatcccat tactcaggca gtgagaatat taccacaacac gtagatcttc	1200
aaggcatgca cccctccctc gttcccttgt ctagtggtcc ctggggctca ttgttcccat	1260
ttttatgttc atgtgtattc aatatatagc tcccacttac aggtgagaac atgcagtatt	1320
tggtttcctg tttttacgtt agttcactta aaataatgcc ttccagctcc aaccatgttg	1380
ctggaaagga tatggctttg tttttattta tggctgtata gtattccctg gtgtatatgt	1440
accacgtttt ctttaccxaa tccactgctg atgggcacct aggtggattc caggtccttg	1500
atattgtgaa tagcactgca ataaacctac agatgcgtgt gtgtttttga ttgaatgaac	1560
aattttcctt tgagtatata cccagtagtg gggttgctgg attgagtcgt agctatatat	1620
taagatcttt gagaactctt cacattttgc atattaactc tattatatat gtggtttgca	1680
aatatttttt tcatacagta gattgtctct tcaactcgtt gatTTTTTaa attgtatagt	1740
acctttgttt taatgtaatc ttatgtgtcc atttttcttc actttgtttt attttagtag	1800
ttatacagtt tcaggctcta tgctttaaat cttttatcca atttgagttt atttttatac	1860
atggtgtgag ataaagatcc aattttcttc ttctccctct ctgtcgccag gctggattgt	1920
aatggcgcaa tcttggtca ctgcaacctt ggcctcctgg gttcaagtga ttctcctggc	1980
tcagcctcct gagtagctgg gattacaggc acccgccacc acaccagat aatttttgta	2040
tttttagtag agatgggggt tcaccagggt ggccaggctg gtctcgaact cctgacctca	2100
ggtgatccac ccgccttggc ctcccaaagt gctgagatta caagtgtgag ccaccgtgcc	2160
tgacccaat tttattctac atatacatat acatatccag ttctgccaac accacttggt	2220
gaagagactc ccctttctgc attgtgtaat tttggcatct ttgtcaaaaa tcaattgatg	2280
gtaaatggat gaatttattt ctaggctcta tattctgttc cattgggtgta gatattctgtt	2340
tttaggccaa tacaatgctg ttccaaagac tatagctttg tagtagattt taaagtcagg	2400
tagtatgatg cctctagctt tgttcttttt gttaaagatt gctttggcta ttagtgtctt	2460
gtggttcctt gtgaatttta ggattttctt cctattttctg tgaaaaatgc tactggaatt	2520

PRD3345WOPCT_SeqListing.txt

ttgagagaga atcaatctgt agatctcatt acatagttaa atattttaac aatccatgga	2580
catagaatat ttttctgtct atatttgtgt cttcttcagt ttctttcatc aaagttgtat	2640
agttttggtg ttagactctc tcgccttctt ggtaaaatth attcctaagt atttatttat	2700
ttatttttat ttatttattt ttttgagatg gagtcttgct ctgtcaccca ggctggagtg	2760
cagtgggtgcg atctcagctc actgcaacct ccacctcctg ggttcacacc attctcctgc	2820
ctcagcctcc caagtagctg ggactacagg cgcccgccac cacacttggc taattttttg	2880
tattttttta gtagagatgg ggtttcacca tgtagccag gatgggtctcg atcccctgac	2940
ctctggatcc gcgaaccttg gcctcccaaa gtgctgggat tacaggcgtg agccactgca	3000
cctggccctt attcctcagt attttatgtt tgttttgttt gttttgtttt ggggtttttt	3060
ttagctattg taagttgatt tttctgattt cttttttgga aagttcattg ttagtgtatg	3120
gaaactctac tgatttttgt atgttaattt ttgtatcctg caactttcca gactttaaat	3180
tagttctaag agatttagtt agtgtcttta gagttctaga tggttaagatt atattgtctg	3240
cagagacaat ttaattattt tcttctgatt tagatgcctt taaatctttc tcttgccata	3300
ttgctgtggc taaaacttgc tgtattatgt tgcataaaag tgagaggagt gggcatcctg	3360
gtcttggtcc tgatcttaga gaaagagctt tcagggtttt accattgagt ataattgttag	3420
ctgtggcctg tcatacatgg cctttattat gttgagttat actacccta taccaaatat	3480
gttgagagtt tttatcatga aaatgtgctt ttcagtgcac taaattttta ttaccatctc	3540
tatttttcaa actagaaaag cgatttgctt aaattaatta taaaataata atacatattt	3600
taatccattt atcaattaca atttacatag gtactgttgt aactgctgct gtttgcataa	3660
aataactcaa taaaaatact acaatcttaa atcagtacat agtgaaatat cattcaaact	3720
gaatcaatcc atagacacca actagattgg tgaacagctt atgtgtaata ctagaaatga	3780
ttagtgttcc caacatgtgc agtaaaatac aataataata tctcacatga tgcaatagtt	3840
aaagtgaat atagctctat caaaataata aagttgtgta acacaaatgt attttatact	3900
gcttaggttt taaaatttga ataaattaaa attaaataaa atgaaatgtt aagttttttg	3960
ctagccacat tcagatgttc aatagccaaa tatgactagt ggctaccgta ttagatagaa	4020
cagttctaga ttctacattg gtgtttgtta atgtttcaca ctctcagtgt ttctaatgt	4080
tcaacatgtc tctttctcct gctttttttt aaattatagt ttctaattct tcctatctag	4140
cacattgcct gaatgtcagt gaatattatg taaatgaata aataaacaac cctatacttt	4200
gccac	4205

<210> 14

<211> 4205

<212> DNA

<213> Homo sapiens

<400> 14

ataaaattaa tagcgttaaa tgctcatgat gtgccattac gtggacttta acaatatttt 60

gatgacatta cacttcacat aacatccttc ctaaaagaca aaattattaa ttagataata 120

PRD3345WOPCT_SeqListing.txt

gctttaaatt	ttaaaactag	ataaactaac	cccttcccc	agtaggtttt	gttatTTtag	180
aattgtgcag	ggcttttagta	ttttttcatc	ttatTTTTTT	aattgacaga	taaaaattgt	240
gtatatTTtg	tgtaaataag	atgttttgaa	atacatatac	attctggaat	ggctagatca	300
acttaattaa	catatgcagt	acctcacaaa	catcatttat	ttgaggcaaa	taaaatccat	360
tctgttagaa	ttttcaagt	taagcacatt	gctgttaact	ttaatcactg	tgTTgcacaa	420
tagatctcct	agattcatcc	atgttatcat	aaatgacaga	attttcttct	ttttaaggct	480
gaataatagt	gcatatgcgt	atatatgtat	gtataaataa	aacgttttca	ctatccgttc	540
atccattgat	agacacttag	gttgattcta	gaatatgcc	caatggacaa	tggagtacag	600
ctgtctctac	agatggattt	tctttctttg	gctatatacc	aagaaatgaa	atgtctagat	660
catgtggtaa	ttctgttttt	taattttttt	acaactcttc	ctaacagttt	tccataatag	720
ctgtactaat	ttacatttcc	acaaacaatg	tacaagaatt	ccctttcctc	tacatcctaa	780
tacttgttat	cttttgTTTT	tctgataaca	gccattctga	aagggtgtgag	gtaatgtctc	840
attgtagttt	tgatttgaat	tccctgacga	ttagtggttt	taagcatttt	tcatatacca	900
ttggccattt	gtatgtcttg	agaaacatct	attaagatcc	tttgccagta	ttttaattag	960
attattttcc	ttgctattga	attctttaag	atctttatTT	tttttgTgta	tacatagata	1020
catatattat	taacgttgat	tatttatctg	taaatttatt	tttataattt	caacttttat	1080
tatagggttaa	agactacacc	tgcagggtttg	ttgcatgagt	aaattcctga	ttctgaggct	1140
tggagttaca	atgatcccat	tactcaggca	gtgagaatat	taccaaacac	gtagatcttc	1200
aaggcatgca	cccctccctc	gttcccttgt	ctagtggTcc	ctggggTcta	ttgttcccat	1260
ttttatgttc	atgtgtattc	aatatatagc	tcccacttac	aggtgagaac	atgcagtatt	1320
tggtttcctg	tttttacgtt	agttcactta	aaataatgcc	ttccagctcc	aaccatgttg	1380
ctggaaagga	tatggctttg	tttttatTTa	tggctgtata	gtattccctg	gtgtatatgt	1440
accacgtttt	ctttacccaa	tccactgctg	atgggcacct	aggtggattc	caggTccttg	1500
atattgtgaa	tagcactgca	ataaacctac	agatgcgtgt	gtgtttttga	ttgaatgaac	1560
aattttcctt	tgagtatata	cccagtagtg	gggttgctgg	attgagtcgt	agctatatTT	1620
taagatcttt	gagaactctt	cacattttgc	atattaactc	tattatatat	gtggtttgca	1680
aatatttttt	tcatacagta	gattgtctct	tcactccgtt	gattttttta	attgtatagt	1740
acctttgttt	taatgtaatc	ttatgtgtcc	atttttcttc	actttgtttt	atttttagtag	1800
ttatacagtt	tcaggTctta	tgctttaaat	cttttatcca	atttgagttt	atttttatac	1860
atgggtgtgag	ataaagatcc	aattttcttc	ttctccctct	ctgtcgccag	gctggattgt	1920
aatggcgcaa	tcttggtcca	ctgcaacctt	ggcctcctgg	gttcaagtga	ttctcctggc	1980
tcagcctcct	gagtagctgg	gattacaggc	acccgccacc	acaccagat	aatttttgta	2040
tttttagtag	agatgggggt	tcaccagggt	ggccaggctg	gtctcgaaact	cctgacctca	2100
ggtgatccac	ccgccttggc	ctcccaaagt	gctgagatta	caagtgtgag	ccaccgtgcc	2160

PRD3345WOPCT_SeqListing.txt

tgacccaat	tttattctac	atatacatat	acatatccag	ttctgccaac	accacttggt	2220
gaagagactc	ccctttctgc	attgtgtaat	tttggcatct	ttgtcaaaaa	tcaattgatg	2280
gtaaatggat	gaatttattt	ctaggctcta	tattctgttc	cattgggtgta	gatatctggt	2340
tttaggccaa	tacaatgctg	ttccaaagac	tatagctttg	tagtagattt	taaagtcagg	2400
tagtatgatg	cctctagctt	tgttcttttt	gttaaagatt	gctttggcta	ttagtgtctt	2460
gtggttccgt	gtgaatttta	ggattttctt	cctattttctg	tgaaaaatgc	tactggaatt	2520
ttgagagaga	atcaatctgt	agatctcatt	acatagtga	atattttaac	aatccatgga	2580
catagaatat	ttttctgtct	atatttgtgt	cttcttcagt	ttctttcatc	aaagttgtat	2640
agttttggtg	tgtagactct	tcgccttctt	ggtaaaattt	attcctaagt	atttatttat	2700
ttatttttat	ttatttattt	ttttgagatg	gagtcttgct	ctgtcaccca	ggctggagtg	2760
cagtgggtgcg	atctcagctc	actgcaacct	ccacctcctg	ggttcacacc	attctcctgc	2820
ctcagcctcc	caagtagctg	ggactacagg	cgcccgccac	cacacttggc	taattttttg	2880
tattttttta	gtagagatgg	ggtttcacca	tgtagccag	gatggctctg	atcccctgac	2940
ctctggatcc	gcsaaccttg	gcctcccaaa	gtgctgggat	tacaggcgtg	agccactgca	3000
cctggccctt	attcctcagt	attttatgtt	tgttttgttt	gttttgtttt	ggggtttttt	3060
ttagctattg	taagttgatt	tttctgattt	cttttttgga	aagttcattg	ttagtgtatg	3120
gaaactctac	tgatttttgt	atgttaattt	ttgtatcctg	caactttcca	gactttaaat	3180
tagttcta	agatttagtt	agtgtcttta	gagttctaga	tggttaagatt	atattgtctg	3240
cagagacaat	ttaattattt	tcttctgatt	tagatgcctt	taaatctttc	tcttgcctaa	3300
ttgctgtggc	taaaacttgc	tgtattatgt	tgcataaaag	tgagaggagt	gggcatcctg	3360
gtcttgttcc	tgatcttaga	gaaagagctt	tcaggctttt	accattgagt	ataatgttag	3420
ctgtggcctg	tcatacatgg	cctttattat	gttgagttat	actacccta	taccaaatat	3480
gttgagagtt	tttatcatga	aaatgtgctt	ttcagtgc	taaattttta	ttaccatctc	3540
tatttttcaa	actagaaaag	cgatttgctt	aaattaatta	taaaataata	atacatattt	3600
taatccattt	atcaattaca	atttacatag	gtactgttgt	aactgctgct	gtttgcataa	3660
aataactcaa	taaaaatact	acaatcttaa	atcagtacat	agtgaaatat	cattcaaact	3720
gaatcaatcc	atagacacca	actagattgg	tgaacagctt	atgtgtaata	ctagaaatga	3780
ttagtgttcc	caacatgtgc	agtaaaatac	aataataata	tctcacatga	tgcaatagtt	3840
aaagtgaaat	atagctctat	caaaataata	aagttgtgta	acacaaatgt	attttatact	3900
gcttaggttt	taaaatttga	ataaattaaa	attaaataaa	atgaaatgtt	aagttttttg	3960
ctagccacat	tcagatgttc	aatagccaaa	tatgactagt	ggctaccgta	ttagatagaa	4020
cagttctaga	ttctacattg	gtgtttgtta	atgtttcaca	ctctcagtgt	ttcctaattgt	4080
tcaacatgtc	tctttctcct	gctttttttt	aaattatagt	ttctaattct	tcctatctag	4140
cacattgcct	gaatgtcagt	gaatattatg	taaatgaata	aataaacaac	cctatacttt	4200

gccac

4205

<210> 15
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 15
 aataaaacct ctttcgctcc cattgtcacc gaaggacctg acaacctgtc tttctacact 60
 tcgcctacaa tcagtgtcct tcacccttaa ctctgtctct ttccttttat attaggttat 120
 agtgggctct ctattaccaa gcccagtgga atcattttgt cctttattac ctctctgtgt 180
 catctttaag agaaatacat atatatttct ctctacgtag aatggccatc tgtttcttca 240
 tcacctgagg aatcattcaa tatgactttc aaatgaatat tcagagaatt ttctaagtta 300
 gaaacatagg tattcatcta aaatcatttc aaaaaccatc tccctttatt taagaatggt 360
 attctcttct acagaaaagc ctctagtgtt tactggggag atttgtgctg tgggaagaag 420
 gggacagtgc tgaactgcac acaacctaac aaatcaatcc tgataattag tagagtggca 480
 gatggggagc ccagccatgc ycacaccttt ctgagaacca gctcaattcc tatctctgct 540
 ctgacacatt cttgcaggta gttagccact ctctgtgagt tttttttgca ctctgttcat 600
 agttccatta aagaacttgt tatatagctt tctagtcctt tgttgacata tctactaaaa 660
 tgtgaatttc ttaagggcaa gtccatttta tctttatatt tctgcatata tagtttatcc 720
 taagctcatt tattttgaac gaataaattt ggggaggaga caacaaagta tgagagatat 780
 gtttaaaacc tataaatgca aaaccttgaa tggaaagctt gttcttgata gtttttaagt 840
 tcttggatga tgtatttcta gagggtagac agtacctgcc aaggcataaa tttttaataa 900
 agggctcatt ttttaagag atctttaaaa tatcgccgtt tcttaggtct gtgcattgag 960
 atttcagttt atctgtaaca gaactactta tttaggaacc t 1001

<210> 16
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<220>
 <221> modified_base
 <222> (501)..(501)
 <223> a, c, t, g, unknown or other

<400> 16
 accctgttac cagaaaggag tcctaattct gacccaaga gaaggtcctt aaatctcgtg 60
 caagaaagat ttcagggtta gtccacggag taaagtgaag gcaagtttat taagaattaa 120
 aggaataaaa gaatggttac tccataggca gagcagcccc aagggtgct gggttgctat 180
 ttttatgggt atttcttgat tatatgctaa acaacaaaa atggattatt catgagtttt 240
 ctgggaaagg ggtgggtgat tcctggaact gagagttcct cccattttca gaccatatag 300
 ggtaacttcc tgacgtttat aaactgtcat ggtgctggta ggagtgtctt ttagtatgca 360

PRD3345WOPCT_SeqListing.txt

aattcattac aattagagta taatgagcag tgaggatgac caggggtcac tttcttcaca	420
atcttggttt tgggtgggatt tggccatttt ctttacctcc tgctgttcta tcagcaaggt	480
ctttgtgacc tgtatcttgt ngctgacctc ctgtcttata ctgtgagtta gaatgcctaa	540
ccttttgga ctgcagccca gtaggtctca gtcttatttt actgagcacc tattccagat	600
ggagtagatc tggttcaaat gccactgaca acccaaacat ttttttaaaa tgtttagaca	660
tacaaaagga gacaggtaga catataaaag gaaattccaa taacttggtc tccaacttaa	720
agtaagtatg tctttattga aactcatgt gattggaaat gtggaagggc ttttaatgta	780
ttatttaatt attttaacac ctaaaagggg ttggtacat tagtcactcc cattttacag	840
atgagaaagc tgagactgag aaaatgaatt acctggccta gatgtcaaaa caagaagggt	900
gactttgaga gccattgctt ttattaagtg taatattagg ttatctttta aaaactcaag	960
ttagggagaa ctgaaagtct tcaaagagag taaataactc c	1001

<210> 17
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 17	
ttatcctagt tttacctgta ttatcatgtt taatctttta atagccctct tatgaaggca	60
tcagcattac ttaccttcac ttttaaaatt agaaaattaa aaccagaagg agttaagcaa	120
cacacatgag atcacacagc agttggatat tagggatggg gtttgaaccc aagaatttta	180
tcaccaagc cccctttaga ctactgcatt acatagcctg gcatacaaag ccaatgaagt	240
aaaatatgta ctattaaatt aatgatgag gagtcccgtc ccagcagtat aactccaata	300
tgagtaagga catgattaaa acaagttaca aaataggac atatatggaa aagtatttga	360
tgtctatggg atggaaaaga gttaatacct tttccatata aaatgtattt aagataaata	420
ataaaatgat agacacacat tacaatagac aaaggcaaaa aataagcatg cttagtggcc	480
aataataggt ttagactctg rtaattaaac aaatgcaact caaaatctga atgaaatgct	540
aatttaacct atcgaaataa caaattaatt ttaaaaatta attttaaaaa ataatttaaa	600
gttttgaaga ctgtatgggg aaaatgacac attcataccc atacaatagt tgtattacac	660
ttatgcaaag aatgacagaa taaaagaaac atatagtaag cagaaatgca actatttata	720
ttaaatgaaa acataaaatg ccagtgacta ggggtataat taaataggct gtaaaagtag	780
acataactag aactcaaaat ctgagatcag cttttagat atagaagtaa agacattggt	840
ctttcccaa aacttgtgag gtatattctc taagacctaa aatatgtttc ccattcaaaa	900
attcatatat atatgaatat gcatatatta tatgtttatt gcatatataa tttttcatgc	960
aatgttgtag tgttataagt tttaaaatat caggcctaca t	1001

<210> 18
 <211> 1001
 <212> DNA

<213> Homo sapiens

<400> 18

```

tttattaaat gaatgtacaa atgaatagag agtacctttt caaaaataca gttcaatgac      60
tatccataaa aggcaaagaa agcaatcaga ctctcccat caaattttta aaaaaccact      120
ttgttacatt ccgtaaccaa cattctgtga gccttagagc aatttaaagt cattatgcct      180
cagtttccta gtatttaaaa cagtgaatat tacgtttgct ttgtttacac cattatgaca      240
atcaaatttg aaaacatgca ttaaagccct ttaagaaagc atataagtgc gcttccgtgg      300
tgagaaagaa aatatctgca aataagggga ttgatatct gaactgagaa aatatagctc      360
tttctaggta atgtttgagc tgacaagtga gtacatttga atgatttaat ggacacttaa      420
aagtttcttt tcattctaaa tcatatgaag gattcaatta gactttcatc ttaaaacagt      480
aatgcaatta cttctatgat maaacaacat ttttaaaaag tgacaacata cacttttagc      540
ttcaaatttg ttctctgtcc cttcaagctt attctatcac tatataaac taagcaatgt      600
aatacagaac aattctcaat agccaggtaa cttatatattg atgtaggcct gatattttaa      660
aacttataac agtacaacat tgcataaaaa attatatatg caataaacat ataatatatg      720
catattcata tatatatgaa tttttgaatg ggaaacatat tttagggtctt agagaatata      780
cctcacaagt ttttgggaaa gaacaatgtc tttacttcta tatctacaag gctgatctca      840
gattttgagt tctagttatg tctactttta cagcctatct aattataccc ctagtcaactg      900
gcattttatg ttttcattta atataaatag ttgcatttct gcttactata tgtttctttt      960
attctgtcat tctttgcata agtgtaatac aactattgta t                                1001

```

<210> 19

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 19

```

gactttaaat tgctctaagg ctacagaat gttgggttacg gaatgtaaca aagtgggtttt      60
ttaaaaaattt gatggggaga gtctgattgc tttctttgcc ttttatggat agtcattgaa      120
ctgtattttt gaaaaggtag tctctattca tttgtacatt catttaataa ataacttgct      180
ttaaattcta ttaggacaat ttgacctttc ttttcctttc ctactttctc gacaaagttg      240
cctctctgaa caagtgtttg tcatcatata tctgaccccc agcccctact ctgcaggaac      300
agatgaaaca ccctgtgaat ctctcaacac tatgttgtcc aacacaaata taatgtgagg      360
cctctatgta atttaaactt cctagtagcc gcatttttta aaatagaaaa aaaaggtaaa      420
attaatttta ttagtgcatc ttattcaatc taatattcta acttacaata atataaacat      480
tattaatgag atattttgta yttttttggt acaaagtctt tgatatccca tgtatatattt      540
atacttacac acattcaatt tgaactaatt acactaaaag tgctcaatag ctatatgatt      600
gaacagtgca gtctgagggc aattgggact tcttattgac tattttgact cttgggttaa      660
taaaattgaa ataatttcag actttaagtg ggcagttagg aatatatctg ctttcaaagt      720

```

PRD3345WOPCT_SeqListing.txt

taccaaggaa gctctgctag ttaactttat tctcatactc tattatTTTT catacattaa	780
aatgtgaact tcttttaatt gactctgtgg tttgttggtg ttgtttttgt ttttctcctc	840
actttgttct gaccttcttc ttttcctttt cagtaagatt tgtcctgtct ccacaaggac	900
caggcttaga ataggaatag taaatgacct atctggagag taaagaaatg ttcctcttcc	960
cctcaaattc cttttctctt attgaggcct gatttccaca g	1001

<210> 20
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 20 taggacaatt tgacctttct tttcctttcc tactttctcg acaaagttgc ctctctgaac	60
aagtgtttgt catcatatat ctgaccccca gccctactc tgcaggaaca gatgaaacac	120
cctgtgaatc tctcaacact atgttggtcca acacaaatat aatgtgaggc ctctatgtaa	180
tttaaacttc ctagtagccg ctttttttaa aatagaaaaa aaaggtaaaa ttaattttat	240
tagtgcattt tattcaatct aatattctaa cttacaataa tataaacatt attaatgaga	300
tattttgtac ttttttggtg caaagtcttt gatatcccat gtatatTTTA tacttacaca	360
cattcaattt gaactaatta cactaaaagt gctcaatagc tatatgattg aacagtgcag	420
tctgagggca attgggactt cttattgact attttgactc ttgggttaaatt aaaattgaaa	480
taatttcaga ctttaagtgg rcagtttaga atatatctgc tttcaaagtt accaaggaag	540
ctctgctagt taactttatt ctcatactct attatTTTTc atacattaaa atgtgaactt	600
cttttaattg actctgtggt ttgttggtgt tgTTTTgtt tttctcctca ctttgttctg	660
accttcttct tttccttttc agtaagattt gtcctgtctc cacaaggacc aggcttagaa	720
taggaatagt aaatgaccta tctggagagt aaagaaatgt tcctcttccc ctcaaattcc	780
ttttctctta ttgaggcctg atttccacag gagtctcttc atttcttttc tttattatgt	840
tattagtctg ctaacttcaa taatagataa attccaaatt tcagtttcta aaccccaaat	900
ctacttctct ctcagatagt atgccaaatt caggcttatt ttcagcaagg actccggcat	960
gggggatttg aggggtgggt ttctattcca caaagtcatt c	1001

<210> 21
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 21 catacaataa taaggggaga ctttaacacc ccaccaacag tattagacag atcatcaagg	60
cagaaaatta acagatattc aggatctgaa ttcaacgctt gaccaaattg acttaataaa	120
ctccctattc aagaaatggt gctgggataa ctgaatagcc acgtgcagaa gattgaaact	180
ggaccctttc cttacataat atacaaaaat taactcaaat ggattaaaga cttaaattta	240
aatcctaaaa ctatgaacaa cctggaggat aacctaggaa gtataattct ggacatagga	300

PRD3345WOPCT_SeqListing.txt

tctggcaaag	atctcatggg	gaagaaacca	aatgcaattg	caataaaaaac	aaaaattgac	360
aactgggacc	taaataaact	aaagagcttc	tgcacagcaa	aataaactat	caaagagta	420
aacagacaat	ctacagaatg	ggagaaaata	tttgcaaact	atgcatctga	caaaggtcta	480
atatccaaca	tctatgagga	mtttaaaca	atacacaagg	aaaaaaaaa	caaccccatt	540
aaaaagttag	caaaggacat	gaacagacac	ttttcaaaaa	aagacatata	tgcggtcagc	600
cagcatgtga	aaaaatgtgc	aacatcacta	atcattagag	aaatgcaa	taaaactaca	660
attcgatact	gtctcacacc	agtcagaatg	gctgctctta	aaaagtcaat	aaataacaga	720
cactagttag	gttgcaaaga	aaaaccctta	tacacttctg	gtgggaatgt	aaattagtct	780
aaccattgtg	gaaagcaatt	tggtgatttc	tcaaagaact	caaagcagaa	ttaccattca	840
accagcaat	ccattattgg	gtatatccca	aaggaatata	aggtcttcta	tcataaatac	900
acatgcacat	gtatatccat	tgcagcacta	ttcacaatag	caaagacatg	gaatcaacct	960
aatgcctat	aaagagtagg	ctgaataaag	aaaatttggg	g		1001

<210> 22

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 22

aagtcatttt	aaaaatctta	aaaagccaaa	gagaacctgg	gaaatctaga	tgagcacatg	60
tatatattgt	gaacaattgc	tccagggtata	tgggaatttat	ggctctaggat	agaatgtgaa	120
aatgtggaca	aatagctaca	atacaaagca	taattaactt	agtgtcacao	ttgatagcta	180
cacacagcaa	catgagcatt	caaggaaaag	gggaaatcaa	tccaaatgga	actactgagt	240
tcagtagatt	ggcccataat	actctatcct	ggcttcctat	ctcttacctc	ccgccacaaa	300
ttctgcacca	gaacaatctc	agtttctcac	ttagcgctgt	ttgctctttt	atttcccctt	360
ctgtgccttt	cagaggctac	ttctgcttag	aattttctct	tccattgagc	acttgttcaa	420
ttttcattaa	tgttgtaaaa	ctcattcaag	taaaaattcc	tcaatgaaat	catctctgat	480
tgaccaggag	agatctagct	ktcctctctt	ttgttcctcc	atggaatttt	acttgctctt	540
gttttgccct	aagaattaag	cacgtcaa	ggcacatcaa	gggagctaac	gtataacctt	600
gaacattgcc	ctcaggcatt	tattcttagg	catattttgg	ccttatttat	tttatattgt	660
tataattata	ctctaaatac	agttgcatat	ccaagcatct	tttacagtta	accttgatac	720
aataaggctt	taattacata	attctaaaat	attatatcat	attccaatga	gagcctgcac	780
cagttgactt	ctccacatct	ttttggctaa	acacaattgt	tttctatfff	tcataaataa	840
cagaccaaca	tgtgttttgg	gatcccctaa	gggcaggtaa	tcatgaatct	cattgactta	900
ttttatgtca	taagagggat	actaaactat	tccttatfff	ctcactagca	ttactggata	960
gaaattttct	tctgggttac	taaatgacct	ctaagagttg	a		1001

<210> 23

<211> 1001

PRD3345WOPCT_SeqListing.txt

<212> DNA

<213> Homo sapiens

<400> 23

```

gagtctgaat gtctatatgg tatgtatatg atacaatttt tgtaaagctt aaaaataagc      60
ataaatgata ttctattttag aaagagctta tggggtaaag ttgtttaaat aaattatgga    120
ataacaaacg taaaatttta gatagaaatt gcctctgagg gaacgtaagg ggatataact      180
aggcaatagt agcatatgat tttcactgga atttggtagt attttggttg ttaagttggg    240
tggtgggttc gtgaatgttc aattaatcac tataattcac aatttccata ctaactacat      300
aaagttttga tcatattaag tgaatatatt ttttataatt cagaggtaaa caactacttc      360
taaagtataa agagccagca agatataatg aactctgaag aaattttaga gttcactgac      420
taaaaaaaaa atgtattgtc tatatgtgtt ttatttgaat ttcaatgtcc ctacaaagat      480
aaggagactc tgtggcagat rgatctgaag atgatacctg gcgatttcct attcccagtg      540
tgcatggctt tgggtattcc ccacctctgg agtatgggtg agaactgtga cttgctttta      600
atcaattaaa tatgagagtt cacttccaca gttagtgtag attacatggc aaaaaagatg      660
gagtgtcact cttgtgatga taaatgtgac tcgtgcctca gcctcccaag tggctgggat      720
tacaggcgtg cgccaccaag ccctgcta atttatagat atagtatttt tagtagagac      780
aggattttgc tgttttggcc agactggctt gaactcccg cctcaagtga tttgcccgcc      840
tcggcctccc aagggtctgg gatttcaggc ttgagccact gtgtccagcc tcaaatctct      900
attttagagt tgttattaac ctttgtgaaa cagagaactg tagcctttct ttttctttct      960
ttctttcttt ctttcttttt tctttctttc tttctttctt t                                1001

```

<210> 24

<211> 101

<212> DNA

<213> Homo sapiens

<220>

<221> modified_base

<222> (51)..(51)

<223> a, c, t, g, unknown or other

<400> 24

```

tttttagagtt gttattaacc tttgtgaaac agagaactgt agcctttctt ntttctttct      60
ttctttcttt cttttttctt tctttctttc tttctttctt t                                101

```

<210> 25

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 25

```

tcacttccac agttagtgtg gattacatgg caaaaaagat ggagtgtcac tcttgtgatg      60
ataaatgtga ctcgtgcctc agcctcccaa gtggctggga ttacaggcgt gcgccaccaa    120
gccctgctaa tatttataga tatagtattt ttagtagaga caggattttg ctgttttggc      180

```

PRD3345WOPCT_SeqListing.txt

cagactggct tgaactcccc gcctcaagtg atttgcccgc ctcggcctcc caaggtgctg	240
ggatttcagg cttgagccac tgtgtccagc ctcaaactctc tatttttagag ttgttattaa	300
cctttgtgaa acagagaact gtagcctttc tttttctttc tttctttctt tctttctttt	360
ttctttcttt ctttctttct ttctttcttt ctttctttct ttctttcttt ctttctttct	420
tctttctttt ctttctttct tctttcctct ttttctttct ttttttttcg atggggggtg	480
gggagacaga ttgagagagc rcgagagcga gagattatgc acatttgtga gctcttttaa	540
actagctcaa gaaagatcct cagaagacca acatcctaga aatcagtacc aaacacaact	600
agtgtaacat aaatagcttc ctttcttaaa aacagctatt tgaagaaagt tagctgtcaa	660
tcaaaaacag ttttatttga tcagacagag gcaagatgct atggctgttt agccaaagaa	720
aatgacatta tagatacatg taaaattcca acacattgtg taatgtaaca aaacttaagc	780
tgtcttctca ttattattgt tattaattta gatctatatt ctactgactt aggtgagaaa	840
attctccact taccgctttg aaagttaacc aactttctat ggattgttca tttgtttaat	900
agtacaagca atgaaaacat gttttaccat aggtcttaag tatgtagcac cttcctccac	960
cagtatttaa tcatagacct tatactaagg catacaattt t	1001

<210> 26

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 26

acattattat tctaaactag ttattcagta attaaaagga ggaaaagact gctttcaaaa	60
ggtataggta tttgtgaagg ctttttgaga ggtgttaact ctacttaaat ataaatacat	120
accattttga aagttatgag cttcaccata gggaaattca tgttctttga tttagaaact	180
atactcctag ggatatttgt ccaaggacat ttaggagaag gaaaaagaac atggacaact	240
atttattgaa ctcttactac attctagtta gtacttccca ataaaacggt ctgtaacggt	300
gtaagtgttc ttacctgct gtagaatatg gtagccacat gtgaccattg agtatttgaa	360
atgtagtatg caaccgagga tttaaatctt taattttatt taatttttat taactcaaac	420
ttaaatttaa gtagccatgt gtggtatcat attggactgc acagtgagac acatgttaag	480
caatttacag aaattacatt ycttaattat tattatgac tttctattaa ttttattcta	540
cagatatgaa aactgtagga aattaaataa cctgcaaagg tcaccaactt tgaaagtgg	600
atattgaaat ttgaggccag gtagtgtgat gctgtagctc gtgttctgct aggctacttc	660
tctatgcata ttgacttcca atgataggaa aattgttgca tacacttgaa cctaacatga	720
ggtaaaaacc tatgatacta ttgagtgaat attgttaca caatttgcag aaggaaatgc	780
ctttatgaca aattaaata gaagaatgca aaagaatata gactttaaaa gtataattat	840
atgcaaataa tatgagcaag ttgatagtaa tatacaaatt tgaacataaa ttctttttca	900
gtgataaaat tatggataaa tctcaagagt ctttagtgct gtcttttact aggtttaatt	960
ttgtttttgt tgattgttct tcggattaaa tataacaatg a	1001

PRD3345WOPCT_SeqListing.txt

<210> 27
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 27
 aagcctgaaa agactaggat gtgtgtgtgc gttgtgtgta tgtgtatatg tataaggtgtg 60
 catgtgtgtt tgcttatata catgtttatt tgtgtaatag tataataagc agtaggaatg 120
 gagaaataaa actactgttg tttggatatt tactctcttc taggcagtgt tctggatact 180
 ttttagttat tcttcattc tctgcctact ttacattcag tgcatttaag gggttaatga 240
 tccatccaac tacagcaata tttgtcact aaattcattc tgatttggtg tacttggtgg 300
 ttttaaaatc aatacatact tcatcttttg gcagtgcctt tactttttga agttagtata 360
 aatgagtata aatgctgttt aagtataaac aaatctttta gtcccggagg aagactgaaa 420
 ttagcatata tagtaaacad ctttacttag aaaaagaagt tatttttggt tgtgggtttc 480
 tagatttaag aaatgtgtct wtgtgtatag ttacacaaat acgttatctc aaatcatatt 540
 tacagtgtat taaaatggat actttacata atttcaaata tagtatgtac aggggctagc 600
 attaaagcta caaatagttg agtccaggtc taccaaaagt ggatgcaaga cactttctcc 660
 tttttccaga aaggaaaatt gtctgttatg tcctgcctct tctatccttg cctagagtaa 720
 atttctatta gtatttgcaa tcaatcagct taatgtctta tttatcttat tgagagatga 780
 cttctcttta atttttatag gttaattaat ttagataact agatcatatg gaagcatcta 840
 aatgcatgca aaccagaaga atttctctga ctgtctcggg ttacctgatc atggctgtca 900
 cactttggat tctgaaggaa gcagactcta agaatgagtt tggcatgcac taagttgatt 960
 ggggaatatt cttggaaagg aaggaagcag gagtagacag a 1001

<210> 28
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 28
 gatatttact ctcttctagg cagtgttctg gatacttttt agttattctt ccatttctctg 60
 cctactttac attcagtga ttaaggggt taatgatcca tccaactaca gcaatatttt 120
 gtcactaaat tcattctgat ttggtatact tgggtggtttt aaaatcaata catacttcat 180
 cttttggcag tgcctttact ttttgaagtt agtataaatg agtataaatg ctgtttaagt 240
 ataaacaaat cttttagtcc cggaggaaga ctgaaattag catatatagt aaacatcttt 300
 acttagaaaa agaagttatt tttgtttgtg gttttctaga ttttaagaaat gtgtctttgt 360
 gtatagttac acaaatcgt tatctcaa catattttaca gtgtattaaa atggatactt 420
 tacataattt caaatatagt atgtacagg gctagcatta aagctacaaa tagttgagtc 480
 caggctacc aaaagtggat rcaagacact ttctcctttt tccagaaagg aaaattgtct 540
 gttatgtcct gcctcttcta tccttgccga gagtaaat tttctattat ttgcaatcaa 600

PRD3345WOPCT_SeqListing.txt

tcagcttaat gctctattta tcttattgag agatgacttc tctttaattt ttataggtta	660
attaatttag ataactagat catatggaag catctaaatg catgcaaacc agaagaattt	720
ctctgactgt ctcgggttac ctgatcatgg ctgtcacact ttggattctg aaggaagcag	780
actctaagaa tgagtttggc atgactaag ttgattgggg aatattcttg gaaaggaagg	840
aagcaggagt agacagaggg agaattgggc tgctacatag cctcgatgga gacctctgct	900
gatgccgcag agaattctgg agctagaata acccttcagt gttgtactga gttaggataa	960
ggggaatgag tctttagagc cctgggtcag tcattctatc c	1001

<210> 29
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 29	
aaaggaagga agcaggagta gacagaggga gaattgggct gctacatagc ctcgatggag	60
acctctgctg atgccgcaga gaattctgga gctagaataa cccttcagtg ttgtactgag	120
ttaggataag ggggaatgagt ctttagagcc ctgggtcagt cattctatcc aaaccactcc	180
aataaaagag cattcagctt tcttcagcta agcagccctc acgtggggttg tcagctaggg	240
ctttctgctg acagcactat cagcagctgg gagaataagt ccatcattcc tgaaaggcaa	300
gcccatggta tcttacaata tccacaaaa agaccagtaa tatatccatt tctgagaaat	360
taattattga gctaataaca caggagaagg caaaatggta agaatttatt catcctagag	420
acaaatgagt aggtatcaca aacataatga tcaggaaaag aagccagtca caaaagagta	480
tacatgttat aattccattt ycctaagatt aaagcaaaca aagcacacag atgcacgcct	540
gcgtatgtgc gcgtgcgtgc gcgcgcgcgc acacacacac acacacacac acacacagag	600
agctaaaatt aatgtgtggg ttttagaaga ctcaggataa tgtttacatt tagttttctt	660
tttttaattt ggtagaattt ttgtcattaa tttgttcatt ttgttgttat ttataagtat	720
aaagaatttt taaacacaaa taatctatac ttaattttgt gtgtgtattt atttatttaa	780
gaagcataat aggccaggcg tagtggctca cgctgtaat cccaaccctt tgggaagccg	840
aggcgggttg atctcctgaa atcaggagtt gaagaccacc ctgggcaaca tggtgaaacc	900
ccgtctctac taaaatacaa aaaattagct gggcatggtg gcgtgagtct gtagtcccag	960
ctactcagga ggctgggcac gagaatcgct tgagccctgg a	1001

<210> 30
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<220>
 <221> modified_base
 <222> (501)..(501)
 <223> a, c, t, g, unknown or other

PRD3345WOPCT_SeqListing.txt

```

<400> 30
ataacccttc agtggtgtac tgagtttaga taaggggaat gagtcttttag agccctgggt      60
cagtcattct atccaaacca ctccaataaa agagcattca gctttcttca gctaagcagc      120
cctcacgtgg gttgtcagct agggctttct gctgacagca ctatcagcag ctgggagaat      180
aagtccatca ttcctgaaag gcaagcccat ggtatcttac aatatccacc aaaaagacca      240
gtaatatatc catttctgag aaattaatta ttgagctaataaacacaggag aaggcaaaat      300
ggtaagaatt tattcatcct agagacaaat gagtaggtat cacaaacata atgacagga      360
aaagaagcca gtcacaaaag agtatacatg ttataattcc atttccttaa gattaaagca      420
aacaagcac acagatgcac gcctgcgtat gtgcgcgtgc gtgcgcgcgc gcgcacacac      480
acacacacac acacacacac nagagctaaa attaattgtgt gggttttaga agactcagga      540
taatgtttac atttagtttt ctttttttaa tttggtagaa tttttgtcat taatttgttc      600
attttgttgt tatttataag tataaagaat ttttaaacac aaataatcta tacttaattt      660
tgtgtgtgta tttatttatt taagaagcat aataggccag gcgtagtggc tcacgcctgt      720
aatcccaacc ctttggaag ccgaggcggg tggatctcct gaaatcagga gttgaagacc      780
accctgggca acatggtgaa acccgtctc tactaaaata caaaaaatta gctgggcatg      840
gtggcgtgag tctgtagtcc cagctactca ggaggctggg cacgagaatc gcttgagccc      900
tggaggcggg ggttgagtg agccgcgatt gcaccactgc actccagctt gggccacaga      960
gtaagactct gactaaaaaa aaaaaaaaaa aaaaagaagc a                                1001

```

```

<210> 31
<211> 1001
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> modified_base
<222> (501)..(501)
<223> a, c, t, g, unknown or other

```

```

<400> 31
ccataagaaa tagacaacct caaatgagag aagatctgat tgagtagtca ttcaattcta      60
aggccattct gtcaggcat tacacatact ttggcttctt tttttctcat tttaatcagc      120
aggagaattt acttggaagc aaaatctttg gtttcttaac tattattacc cacctgaagt      180
catcatttct gtttattaca tcataatcat ctctacttgc caccaattgt acattcccaa      240
agagcaaatt atgatttcaa gtgaagacaa tggaacagga acagatgtgc tactgaaaga      300
gagacatcct attatcctgg aaatgtactc cataatgaag aacaagggga aaaagatcag      360
aaggatttgt catatatcaa aataaagtct gttctagcag caggattaca tttagagaga      420
tctgctgatg tttccatgca ccattcatag tgctttatgc ttgacatttg catactagag      480
aaatagcaaa attagaccaa naaaaaaatc catatgcaca atttttggca aatctcttag      540
tatagccttt gctgcaattt cctttatcct catttggctt tgtcacacca tattgaccct      600

```

PRD3345WOPCT_SeqListing.txt

gcttccaatt gcggcacttc tgtgtggttc tgactttctt tttcccaaga cctccgttga	660
attgcaccac cagctatattt aatgatcttc ataaaatatac tgtgtctttt aaccctaagg	720
aagtgaagct gacagaatga agactgtgta actattcaaa ttgttttttaa aaactgatgt	780
ttgtgggttac tcggactgtg aagcatgtgt tttatatcaa ttcactcata aatgcagtat	840
tcacttaggc caggcacggt ggcttacgcc tgtaatccca gcactttgaa aggccgagga	900
gggtggatca caaggtcagg agttcgagac cagcctggcc aacatggtga aaccccgctct	960
ctgctaaaga tacaaaaagt tagccggccg tggtggcagg c	1001

<210> 32
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<220>
 <221> modified_base
 <222> (501)..(501)
 <223> a, c, t, g, unknown or other

<400> 32 cataagaaat agacaacctc aaatgagaga agatctgatt gagtagtcat tcaattctaa	60
ggccattctg ctcaggcatt acacatactt tggcttcctt ttttctcatt ttaatcagca	120
ggagaattta cttggaagca aaatctttgg tttcttaact attattacc acctgaagtc	180
atcatttctg tttattacat cataatcatc tctacttgcc accaattgta cattcccaaa	240
gagcaaatta tgatttcaag tgaagacaat ggaacaggaa cagatgtgct actgaaagag	300
agacatccta ttatcctgga aatgtactcc ataataga acaaggggaa aaagatcaga	360
aggattgtc atatatcaaa ataaagtctg ttctagcagc aggattacat ttagagagat	420
ctgctgatgt ttccatgcac cattcatagt gctttatgct tgacatttgc atactagaga	480
aatagcaaaa ttagaccaaa naaaaaaatc catatgcaca atttttggca aatctcttag	540
tatagccttt gctgcaattt cctttatcct catttggctt tgtcacacca tattgaccct	600
gcttccaatt gcggcacttc tgtgtggttc tgactttctt tttcccaaga cctccgttga	660
attgcaccac cagctatattt aatgatcttc ataaaatatac tgtgtctttt aaccctaagg	720
aagtgaagct gacagaatga agactgtgta actattcaaa ttgttttttaa aaactgatgt	780
ttgtgggttac tcggactgtg aagcatgtgt tttatatcaa ttcactcata aatgcagtat	840
tcacttaggc caggcacggt ggcttacgcc tgtaatccca gcactttgaa aggccgagga	900
gggtggatca caaggtcagg agttcgagac cagcctggcc aacatggtga aaccccgctct	960
ctgctaaaga tacaaaaagt tagccggccg tggtggcagg c	1001

<210> 33
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 33

PRD3345WOPCT_SeqListing.txt

atcagcagga	gaatttactt	ggaagcaaaa	tctttggttt	cttaactatt	attaccacc	60
tgaagtcac	atttctgtt	attacatcat	aatcatctct	acttgccacc	aattgtacat	120
tcccaaagag	caaattatga	tttcaagtga	agacaatgga	acaggaacag	atgtgctact	180
gaaagagaga	catcctatta	tcctggaaat	gtactccata	atgaagaaca	aggggaaaaa	240
gatcagaagg	tattgtcata	tatcaaaata	aagtctgttc	tagcagcagg	attacattta	300
gagagatctg	ctgatgtttc	catgcaccat	tcatagtgtc	ttatgcttga	catttgcata	360
ctagagaaat	agcaaaatta	gaccaaaga	aaaaaatcca	tatgcacaat	ttttggcaaa	420
tctcttagta	tagcctttgc	tgcaatttcc	tttatcctca	tttgggtctt	tcacaccata	480
ttgaccctgc	ttccaattgc	rgcacttctg	tgtggttctg	actttctttt	tccaagacc	540
tccgttgaat	tgcaccacca	gctattttta	tgatcttcat	aaaatatctg	tgtcttttaa	600
ccctaaggaa	gtgaagctga	cagaatgaag	actgtgtaac	tattcaaatt	gtttttaaaa	660
actgatgttt	gtggttactc	ggactgtgaa	gcatgtgttt	tatatcaatt	cactcataaa	720
tgcatgtatt	acttaggcca	ggcacggtgg	cttacgcctg	taatcccagc	actttgaaag	780
gccgaggagg	gtggatcaca	aggtcaggag	ttcagagacca	gcctggccaa	catggtgaaa	840
ccccgtctct	gctaaagata	caaaaagtta	gccggccgtg	gtggcaggcg	cctgtaatcc	900
caggtagctg	ggaggctgag	gcagaatcgc	ttgaacctgg	gaggtagagg	tttcagttag	960
gcgagattgt	gccattgcac	tccagcctgg	gcgacagggc	g		1001

<210> 34

<211> 1001

<212> DNA

<213> Homo sapiens

<400> 34

gagagacatc	ctcagaggaa	ttacagttca	ctcgccacaa	ggcacaggcc	tgtggtacaa	60
gtctgagcta	gaacattaag	tcaataagcc	tatactcatt	tttctcatgt	tgctttctca	120
ctcgcctatc	ctaccttgct	ctaaacttcc	catctgtctg	tagaactgtg	gcttaaaaaa	180
aagataaaaa	actgcagaga	ggagagagga	gaaaggcaga	gcagacctaa	aaatcacaaa	240
ctgtgtgatg	taaagtgtca	actggcagat	acacactacc	gccagggtgga	aacacggaac	300
ctagggagag	ggagctgaag	tccactgctc	ttatctagag	aagtctcaga	taatcctgcc	360
aactgggaag	ggaacaaggg	cctagcgtag	tttaaagggtg	gagatggcac	gtcccagtgc	420
gcagagagca	gaagtagaga	gaacttctca	ggagagatcc	ccttaaatta	gcattaaatt	480
actcatttag	ggcctggcgc	rgttgctcac	gcctgtaatc	ccagcacttt	aggaggccga	540
ggagggcaga	tcccaggttc	aagagatcaa	gaccatcctg	ccaacatgg	tgaaacccaa	600
cctctactaa	aaatacaaaa	attagctggg	cgtaggtggcg	cacgcctgtt	gtcccagcta	660
ttcaggaggc	tgaggcagga	aaatcgctag	aacctgggag	gtggagggtt	cagttagccg	720
agatagcacc	actgcactac	agcctggtga	caaggcaaga	ctccatctca	agaaaagaaa	780
aaaatactaa	tttagttgca	agagtggagg	cgaggaagat	gagaattatg	aaaaggggca	840

PRD3345WOPCT_SeqListing.txt

cctacatact	taaaacacaa	tttactgac	atttatttac	tgtttatact	tggatagaat	900
ataaagaaaa	caagattcta	ccccgctcta	gcaaggagaa	agctaacatt	atgcatgcac	960
taagctcaca	tgcatatact	atttcattta	atcctcacia	c		1001

<210> 35
 <211> 1001
 <212> DNA
 <213> Homo sapiens

<400> 35						
atatccagag	ggagagagaa	tgatattact	cccaatatcg	tagaagtgta	cagccccct	60
gtgatattgt	tcttaatatc	cgtgggggtga	gtatgatatt	actcccaata	tagaaggggg	120
aagtacaccc	tcctgtgata	ctgttcctaa	tatccaccgg	gggtgagaat	gatattactc	180
ccaatatcgc	aggaggtgta	catccctctg	tcacattgtt	cgtaatgttt	aacgggaaag	240
ataatattac	tcgaaatata	gttaataccc	tgtgtgtcca	ccccctgtg	atataattag	300
taatatccag	ggggagagga	aggtgatatt	actcccatg	tcacgggggg	tgtccaccct	360
cctgtgatat	gatccgtaat	atccaggggtg	ggagaggggg	gcgatattac	tctcaatgtc	420
gcgggggggtg	tccaccccc	tgtgatatgg	tttghtaatat	ccggggggcg	agagggggcat	480
gatattactc	tcaatatctt	rcgcaccgtt	tttgtacacc	ctctctgata	tagtttgcaa	540
tatccaggaa	gggagaggat	gatattactc	cccatatcgc	aggggggtgtg	cacctctctg	600
tgacagcggt	tgtattatcg	gtggggaagt	gtatgatata	attccctata	tcgcagaagg	660
tgtacacgcc	cttgtgatat	tgttcataat	atccagttgg	agaggggatg	atattactcc	720
ccatttgtag	ggggcgagaa	cccttctgtg	atattgttcg	tactatccgg	gaggtgggga	780
gaggatgata	ttactcttca	tattgcaggg	agtgtacacc	cccctatgat	atTTTTattc	840
taccaagggt	gggtagaggt	tgatattact	cccatgact	caggggtgta	cacccccctg	900
tgatattttt	tgtaatgtcc	aaggtggggc	agaggatatt	acttcccatg	tctgataggg	960
tgacacgcc	tttgtgatat	tgtttgtaat	atccagagtg	g		1001